US Pat. No. 10,188,691

PROTEIN INTERFACES

SyntheX, Inc., San Franc...

1. A non-naturally occurring peptide of fewer than 30 amino acid residues which interacts with RAD51 Associated Protein 1?s (RAD51AP1?s) binding site on human RAD51 recombinase (RAD51), wherein the non-naturally occurring peptide consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 66, or SEQ ID NO:67, wherein any of the amino acids are optionally D-amino acids.
US Pat. No. 10,189,204

COMPOSITE FEEDSTOCK FOR ADDITIVE MANUFACTURING

Desktop Metal, Inc., Bur...

1. A feedstock for additive manufacturing, the feedstock comprising:a core including a binder system and a powder material suspended in the binder system, the powder material including a sinterable powder, the binder system including a primary binder and a secondary binder, a net shape of the powder material retainable by the primary binder during a primary debind process, a net shape of the powder material retainable by the secondary binder during a thermal sintering cycle, and at least one of the primary binder and the secondary binder including a first polymer; and
a jacket about the core, the jacket including a second polymer, and the jacket having a mechanical performance greater than a mechanical performance of the core at a temperature substantially below an extrusion temperature for the feedstock.
US Pat. No. 10,189,716

ZEOLITE MONOLITH AND METHOD OF MAKING THE SAME, COMPOSITE WITH ZEOLITE MONOLITH AND METHOD OF MAKING THE SAME, AND METHOD FOR INCORPORATING TWO OR MORE ZEOLITE MONOLITHS

1. A method of manufacturing a porous monolithic zeolite structure including the steps of:(a) taking a porous monolithic substrate;
(b) forming one or more zeolites on the substrate; and
(c) substantially or completely removing said substrate.
US Pat. No. 10,188,692

METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS

Stealth Biotherapeutics C...

1. A method for treating macular degeneration in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a peptide represented by the formula D-Arg-2?6?-Dmt-Lys-Phe-NH2 or Phe-D-Arg-Phe-Lys-NH2, where the subject has drusen.
US Pat. No. 10,189,974

TIRE

SUMITOMO RUBBER INDUSTRIE...

1. A tire composed of a rubber composition which comprises a rubber component comprising a modified butadiene rubber and silica and has a pure water contact angle of from 125° to 140°,wherein the rubber composition comprises the modified butadiene rubber and silica as a masterbatch, and
wherein the masterbatch is made by a kneading step for kneading each of the components, said kneading step comprising:
an X-kneading step for preparing the masterbatch comprising the modified butadiene rubber and silica,
a Y-kneading step of adding the remaining compounding agents and additives other than vulcanizing agents and vulcanization accelerators to the masterbatch and then kneading a resultant mixture, and
a final F-kneading step of adding vulcanizing agents and vulcanization accelerators to the kneaded product obtained in the base kneading step and then kneading a resultant mixture.
US Pat. No. 10,188,693

METHODS FOR TREATMENT OF ATHEROSCLEROSIS

Stealth Biotherapeutics C...

1. A method for delaying onset, ameliorating or eliminating statin side effects in a subject in need thereof, the method comprising administering an effective amount of a peptide D-Arg-2?6?-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof, wherein the peptide is chemically linked to the statin, wherein the statin side effect comprises one or more of rhabdomyolysis, kidney failure, diabetes, memory loss, and decreased coenzyme Q10 levels.
US Pat. No. 10,192,025

ROTAVIRUS PARTICLES WITH CHIMERIC SURFACE PROTEINS

Novartis AG, Basel (CH)

1. A chimeric protein complex comprising a trimer-forming rotavirus VP7 surface protein linked to a heterologous protein, wherein the rotavirus VP7 surface protein is linked to the heterologous protein non-covalently by a two-part adapter system, wherein the first part of the adapter system comprises a first adapter polypeptide that is fused to the rotavirus VP7 surface protein optionally via a linker sequence, and the second part of the adapter system comprises a second adapter polypeptide that is fused to the heterologous protein optionally via a linker sequence, wherein the first and the second parts of the adapter system form a stable complex with each other, and wherein the chimeric protein complex is capable of recoating and thereby forming a part of an outer layer of double-layered rotavirus particles in vitro.
US Pat. No. 10,188,694

PEPTIDE FOR SKIN REGENERATION OR WOUND TREATMENT AND USE THEREOF

BIO PEP CO., LTD., Seoul...

1. A peptide selected from the group consisting of the amino acid sequence consisting of SEQ ID NO: 1 or the amino acid sequence consisting of SEQ ID NO: 2, wherein the N- or C-terminal of the peptide is attached to a protective group selected from the group consisting of an acetyl group, a fluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group or a polyethylene glycol (PEG) group.
US Pat. No. 10,188,695

CALCINEURIN INHIBITORS FOR USE IN THE TREATMENT OF LESIONAL VESTIBULAR DISORDERS

Sensorion, Montpellier (...

1. A method for restoring or ameliorating the functionality of the vestibular endorgans in a subject affected by a lesional vestibular disorder, comprising the step of systemically administering to the subject a therapeutically effective amount of a pharmaceutical composition consisting essentially of a calcineurin inhibitor,wherein the lesional vestibular disorder is selected from the group consisting of drug-induced ototoxicity and excitotoxicity,
wherein the calcineurin inhibitor is selected from the group consisting of tacrolimus, cyclosporin A, CN585 and their derivatives; and
wherein administration of the calcineurin inhibitor restores or ameliorates the functionality of the vestibular endorgans in the subject affected by a lesional vestibular disorder.
US Pat. No. 10,188,696

PHARMACEUTICAL COMPOSITIONS

Novartis AG, Basel (CH) ...

1. A capsule for oral administration comprising a pharmaceutical composition comprising:(i) alisporivir in an amount of about 15% to about 20% by weight of the composition,
(ii) water in an amount of about 2% to about 10% by weight of the composition and a carrier medium comprising
(iii) a lipophilic component;
(iv) a surfactant; and
(v) a hydrophilic component comprising ethanol, wherein ethanol is present in an amount of about 10 to about 25% by weight of the composition.
US Pat. No. 10,188,697

GLYCOPEPTIDE COMPOSITIONS

XELLIA PHARMACEUTICALS AP...

1. A pharmaceutical composition comprising a glycopeptide antibiotic; an excipient selected from N-acetyl-D-Alanine and N-acetyl-Glycine; and an amino acid.
US Pat. No. 10,189,979

NUCLEATED PHTHALATE-FREE PP HOMOPOLYMERS FOR MELT-BLOWN FIBERS

BOREALIS AG, Vienna (AT)...

1. A polypropylene composition suitable for the production of meltblown PP fibers comprising:(A) a propylene homopolymer, produced with a Ziegler-Natta catalyst (ZN-C), and
(B) a polymeric nucleating agent,
wherein the polypropylene composition has
i) a melt flow rate MFR2 (230° C./2.16 kg) measured according to ISO 1133 of 90 to 5000 g/10 min, and
ii) a difference between melting temperature (Tm) and crystallization temperature (Tc), (Tm?Tc) of <45° C., and
wherein the propylene homopolymer has been visbroken and has an MFR2 of 400 to 3000 g/10 min.
US Pat. No. 10,188,698

SAPOSIN C-DOPS: A NOVEL ANTI-TUMOR AGENT

1. A method for decreasing tumor volume in a subject comprising the step of administering to the subject a composition comprisinga phospholipid, wherein the phospholipid is phosphatidylserine;
an isolated saposin C-related polypeptide, wherein the polypeptide has an amino acid sequence at least 85 percent identical to SEQ ID NO: 2 and wherein the polypeptide includes amino acids 24-40 of SEQ ID NO:2; and
wherein the phospholipid forms a nanovesicle incorporating the polypeptide.
US Pat. No. 10,189,980

PROCESS FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION

The Yokohama Rubber Co., ...

1. A process for producing a thermoplastic resin composition having a continuous phase comprising (A) an ethylene-vinyl alcohol copolymer and (B) a polyamide resin (B) and a dispersed phase comprising (C) an acid-modified polyolefin elastomer, wherein the process comprising:(I) kneading the ethylene-vinyl alcohol copolymer (A) and the acid-modified polyolefin elastomer (C) to form a kneaded material in which the acid-modified polyolefin elastomer (C) is dispersed in the ethylene-vinyl alcohol copolymer (A), subsequently,
(II) adding the polyamide resin (B) to the kneaded material obtained in step (I) and further kneading them, and subsequently,
(III) adding an end-capping agent (D) for the polyamide resin (B) in an amount of 0.1 to 5 parts by weight based on 100 parts by weight of the polyamide resin (B) to a kneaded material obtained in step (II) and melt-kneading them at or above the melting point of the polyamide resin (B).
US Pat. No. 10,190,236

HIGH STRENGTH AND HIGH MODULUS ULTRA-HIGH MOLECULAR WEIGHT POLYETHYLENE FIBERS

RELIANCE INDUSTRIES LIMIT...

1. A compact polymeric gel comprising:i. ultrahigh molecular weight polyethylene (UHMWPE) in an amount ranging from 2 to 40% with respect to the total mass of the gel;
ii. at least one nucleator in an amount ranging from 0.05 to 4.0% with respect to the total mass of the gel;
iii. at least one filler in an amount ranging from 0.1 to 1.5% with respect to the total mass of the gel; and
iv. at least one fluid medium;
wherein said UHMWPE is disentangled-UHMWPE or is a combination of entangled-UHMWPE and disentangled-UHMWPE such that the amount of entangled-UHMWPE is equal to or less than the amount of disentangled-UHMWPE.
US Pat. No. 10,188,699

CAPCNA PEPTIDE THERAPEUTICS FOR CANCER

1. A method of inducing cell death in a breast cancer cell, a leukemia cell, or a premalignant breast cell, the method comprising administering a therapeutically effective amount of a composition comprising a cancer-specific proliferating cell nuclear antigen (caPCNA) peptide molecule, wherein the caPCNA peptide molecule comprises an amino acid sequence selected from LAIPEQEY (SEQ ID NO: 2), LGIAEQEY (SEQ ID NO: 3), LGIPAQEY (SEQ ID NO: 4), LGIPEQAY (SEQ ID NO: 6), LGIAEAEY (SEQ ID NO: 7), LGIPEAAY (SEQ ID NO: 8), LGIAEQAY (SEQ ID NO: 9), and LGIAEAAY (SEQ ID NO: 10), and wherein the cell has a mutation in a deoxyribonucleic acid (DNA) repair protein.
US Pat. No. 10,189,981

HIGH-STRENGTH CROSS-LINKED POLYMER PHOTONIC CRYSTAL FILM

XIAMEN UNIVERSITY, Xiame...

1. A method for preparing a cross-linked polymer photonic crystal film, comprising the steps of:(a) preparing a first emulsion by:
polymerizing a hydrophobic monomer and a hydrophilic monomer having epoxy groups in water to provide a first self-assembled unit of monodispersed polymer microspheres having a hydrophobic core and a hydrophilic shell with surface epoxy groups; and
dispersing the monodispersed polymer microspheres of the first self-assembled unit into water under normal conditions of temperature and pressure to obtain the first emulsion having a concentration of polymer microspheres ranging from 5 wt % to 30 wt %;
(b) preparing a second emulsion by:
polymerizing a hydrophobic monomer and a hydrophilic monomer having carboxyl groups or amino groups in water to provide a second self-assembled unit of monodispersed polymer microspheres having a hydrophobic core and a hydrophilic shell with surface carboxyl groups or surface amino groups; and
dispersing the monodispersed polymer microspheres of the second self-assembled unit into water under normal conditions of temperature and pressure to obtain a second emulsion having a concentration of polymer microspheres ranging from 5 wt % to 30 wt %;
(c) successively coating the first emulsion and the second emulsion onto a flat substrate in any order; and
(d) evaporating the water to enable a self-crosslinking reaction between the surface epoxy groups of the first self-assembled unit and the surface carboxyl groups or the surface amino groups of the second self-assembled unit to form said cross-linked polymer photonic crystal film.
US Pat. No. 10,190,237

METHOD FOR PREPARING SALT-RESISTANT AND DETERGENT-RESISTANT ALGINATE FIBER

QINGDAO UNIVERSITY, Qing...

1. A method for preparing a salt-resistant and detergent-resistant alginate fiber, wherein the fiber is obtained by contacting and infiltrating an alginate fiber with an adjuvant solution for 1-300 minutes, washing after the infiltration is completed, and then drying; the adjuvant solution is prepared by dissolving a combination of one or more of boric acid, borate, tetraborate, pentaborate, metaborate or perborate in water; the mass fraction of the adjuvant in the adjuvant solution is 0.1-8%, the alginate fiber is contacted with and infiltrated in the adjuvant solution at a temperature of 10-70° C. for a time period of 1-300 minutes, and the pH value of the adjuvant solution is 8-11; and the mass ratio of the alginate fiber to the adjuvant is 3-100:1.
US Pat. No. 10,188,701

COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS

HEAT BIOLOGICS, INC., Du...

1. A heterologous chimeric protein comprising:(a) a first domain comprising a portion of SIRP? (CD172a) that is capable of binding a SIRP? (CD172a) ligand,
(b) a second domain comprising a portion of CD40 ligand (CD40L) that is capable of binding a CD40L receptor, and
(c) a linker linking the first domain and the second domain and comprising a hinge-CH2-CH3 Fc domain.
US Pat. No. 10,189,984

THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE

LG CHEM, LTD., Seoul (KR...

1. A thermoplastic resin composition, comprising:100 parts by weight of a base resin that comprises greater than 0% by weight to 35% by weight of a diene-based graft copolymer, greater than 0% by weight to 30% by weight of an acrylic graft copolymer, and 35 to 85% by weight of a copolymer of a vinyl cyanide compound and an aromatic vinyl compound; and
greater than 1 part by weight of a polyester-based elastomer having a melt index of 0.1 to 10 g/10 min (230° C., 2.16 kg).
US Pat. No. 10,189,217

METHOD FOR PREPARING THERMOPLASTIC PREPREG AND THERMOPLASTIC PREPREG PREPARED THEREBY

KOLON INDUSTRIES, INC., ...

1. A method for preparing a thermoplastic prepreg, comprising:laminating a thermoplastic resin film having a crystallization degree in a range of 1 to 20% on at least one surface of a matrix fiber to give a laminate; and
heating the laminate to a higher temperature than a melting point of the thermoplastic resin film, then, pressing the heated laminate,
wherein the thermoplastic prepreg has a weight variation per unit area of 3-5%,
said weight variation per unit area being determined by the following equation (I) or (II):
weight variation per unit area (%)=[(W0?W1)/W0]×100  (I)
weight variation per unit area (%)=[(W1?W0)/W0]×100  (II)
wherein W0 is an average weight of 10 samples of the thermoplastic prepreg, and
W1 is a weight of the samples which show the greatest difference from the average weight W0.
US Pat. No. 10,188,705

DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY

Icahn School of Medicine ...

1. A method for treating an acid sphingomyelinase deficiency (ASMD), comprising:a. administering to a human subject in need thereof one or more initial doses of 0.1 mg/kg recombinant human acid sphingomyelinase (rhASM); and
b. administering sequentially escalating higher doses of rhASM to the human subject if the subject does not manifest one or more moderate or severe adverse events, wherein the higher doses are from 0.1 mg/kg to 1.0 mg/kg higher than the previous dose.
US Pat. No. 10,188,706

PLASMINOGEN ACTIVATOR MUTANTS AS ANTI-FIBRINOLYTIC AGENTS

1. A method for inhibiting the fibrinolytic activity of tPA (tissue plasminogen activator) and uPA (urokinase plasminogen activator) in a subject suffering from a disorder or condition associated with fibrinolysis, with the proviso that said disorder or condition is not a brain or neural disorder or trauma, the method comprising:administering to said subject a therapeutically effective amount of at least one tPa mutant, said mutant being selected from the group consisting of:
(a) a tPA mutant designated tPASer481Ala comprising the amino acid sequence as denoted by SEQ ID NO. 1, or a derivative thereof comprising the amino acid sequence as denoted by SEQ ID NO. 12; and
(b) a tPA mutant designated tPASer481Ala-DS comprising the amino acid sequence as denoted by SEQ ID NO. 2, or a derivative thereof comprising the amino acid sequence as denoted by SEQ ID NO. 13;
or of a composition comprising the same.
US Pat. No. 10,188,707

ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF

Berg, LLC, Framingham, M...

1. A pharmaceutical composition comprising enolase 1 (Eno1) or a fragment thereof and a muscle targeting peptide, wherein the Eno1 or a fragment thereof and the muscle targeting peptide are in a complex;wherein the Eno1 or a fragment thereof has glycolytic activity and is present in a therapeutically effective amount; and
wherein the muscle targeting peptide is a smooth muscle targeting peptide, a skeletal muscle targeting peptide, or a smooth muscle and skeletal muscle targeting peptide.
US Pat. No. 10,189,989

POLYESTER MIXTURE INCLUDING POLYETHYLENE 2,5-FURANDICARBOXYLATE

BASF SE, (DE)

6. A polyester mixture comprising:i) from 95 to 99.95% by weight, based on components i and ii, of a polycyclohexylenedimethylene 2,5-furandicarboxylate, and
ii) from 0.05 to 5% by weight, based on components i and ii, of polyethylene 2,5-furandicarboxylate.
US Pat. No. 10,188,708

ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF

Berg LLC, Framingham, MA...

1. A method of decreasing blood glucose in a subject with elevated blood glucose, the method comprising administering to the subject a pharmaceutical composition comprising Enolase 1 (Eno1) or a fragment thereof, thereby decreasing blood glucose in the subject, wherein the Eno1 or a fragment thereof has glycolytic activity and is present in a therapeutically effective amount.
US Pat. No. 10,188,710

REGULATORY T CELL EPITOPE AND HEPATITIS C VIRUS HOMOLOG

Rhode Island Council on P...

1. A pharmaceutical composition comprising an isolated T-cell epitope peptide adapted to repress an immune response and a pharmaceutically acceptable carrier or excipient; said peptide consists of an amino acid sequence of PLLLLLLXLPXRA (SEQ ID NO:5), wherein X is an amino acid and does not have to be the same amino acid in each occurrence in a given sequence.
US Pat. No. 10,188,711

PEPTIDE CONJUGATED PARTICLES

Northwestern University, ...

1. A composition comprising surface functionalized biodegradable particles comprising encapsulated allergen or one or more antigenic epitopes thereof, wherein the particle has a negative zeta potential of about ?100 mV to about ?30 mV.
US Pat. No. 10,189,993

SILOXANE COMPOSITION AND METHOD FOR PRODUCING SAME

SHIN-ETSU CHEMICAL CO., L...

1. A method of preparing a siloxane composition, comprising:a step of producing a crosslinked organopolysiloxane having a weight-average molecular weight of 5,000 to 300,000,000 and containing 0.1 to 50 moles of silethylene linkages per 1,000 moles of siloxane units by hydrosilylation of an organopolysiloxane having a structure of formula (1) below with an organohydrogenpolysiloxane having a structure of formula (2) below
M?MVi?D?DVi?T?TVi?Q?  (1)
M?MH?D?DH?T?TH?  (2)(wherein M is R3SiO1/2, MVi is R2PSiO1/2, D is R2SiO2/2, DVi is RPSiO2/2, T is RSiO3/2, TVi is PSiO3/2, MH is R2HSiO1/2, DH is RHSiO2/2, TH is HSiO3/2 and Q is SiO4/2, each R being independently an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms that has no aliphatic unsaturated bonds and P being an alkenyl group represented by —(CH2)a—CH?CH2 (where “a” is 0 or an integer from 1 to 6); and ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ? and ? are each independently 0 or a positive number, with the provisos that ?, ? and ? are not all 0, ?+?+??2, ?, ? and ? are not all 0, and ?+?+??2) in an amount of solvent that is at least 8 times the combined weight of the polysiloxanes of formulas (1) and (2) and using a platinum group metal compound, andafter obtaining the crosslinked organopolysiloxane using an organic solvent selected from among toluene, hexane, xylene and methyl ethyl ketone as the solvent: adding a low-viscosity organopolysiloxane as a solvent, and distilling off the organic solvent by heating under reduced pressure so as to give a composition that contains no organic solvent.
US Pat. No. 10,188,713

METHODS AND MATERIALS FOR TREATING CANCER

Mayo Foundation for Medic...

1. A composition comprising nucleic acid encoding an HIF-2? antigen, a SOX-10 antigen, and a C-MYC antigen, wherein said composition comprises less than 100 separate nucleic acid molecules.
US Pat. No. 10,189,995

ASPHALT COMPOSITION

Asahi Kasei Kabushiki Kai...

1. An asphalt composition, comprising0.5 parts by mass or more and 20 parts by mass or less of a block copolymer, and
100 parts by mass of an asphalt;
wherein the block copolymer comprises a polymer block (A) mainly comprising a vinyl aromatic monomer unit, and a copolymer block (B) comprising a conjugated diene monomer unit and a vinyl aromatic monomer unit; the content of the vinyl aromatic monomer unit in the block copolymer being 20% by mass or more and 60% by mass or less;
wherein a content of the polymer block (A) in the block copolymer is 10% by mass or more and 40% by mass or less;
wherein a hydrogenation rate of a double bond in the conjugated diene monomer unit of the block copolymer is 40% or more and 100% or less;
wherein the asphalt has a colloidal index ((a saturate fraction content+an asphaltene fraction content)/(a resin fraction content+an aromatic fraction content)) of 0.30 or more and 0.54 or less, and a saturate fraction content of 11% by mass or less,
wherein the conjugated diene monomer unit of the block copolymer comprises a conjugated diene monomer unit (a) derived from a 1,2-bond and/or a 3,4-bond and a conjugated diene monomer unit (b) derived from a 1,4-bond, and
wherein a total content of the conjugated diene monomer units is 100% by mass,
wherein a content of an alkenyl monomer unit (a1) in the conjugated diene monomer unit (a) hydrogenated is 10% by mass or more and 50% by mass or less,
wherein a content of an alkenyl monomer unit (b1) in the conjugated diene monomer unit (b) hydrogenated is 0% by mass or more and 80% by mass or less, and
wherein a sum of contents of a non-hydrogenated conjugated diene monomer unit (a2) after hydrogenation and a non-hydrogenated conjugated diene monomer unit (b2) after hydrogenation is 0% by mass or more and 90% by mass or less.
US Pat. No. 10,188,714

YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF

GlobeImmune, Inc., Louis...

1. A method to reduce tumor burden, inhibit tumor growth, and/or increase survival of an individual who has a cancer that expresses MUC1, comprising administering to the individual an immunotherapeutic composition, wherein the immunotherapeutic composition comprises:a) a yeast vehicle;
b) at least one MUC1 antigen expressed by the yeast vehicle, wherein the MUC1 antigen comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:25 or to positions 92-566 of SEQ ID NO:25, and wherein the MUC1 antigen comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acids L184, Y232, L233, V240, Y241, L242, Y483, V497, L535, F536, and Y551.
US Pat. No. 10,188,715

SWINE DYSENTERY VACCINE

AQUILON CYL SOCIEDAD LIMI...

1. A method of eliciting an immune response against Brachyspira hyodysenteriae in an animal comprising administering to said animal a composition comprising a dose of a single strain of Brachyspira hyodysenteriae, wherein no other Brachyspira hyodysenteriae strain is present in the composition, wherein the single strain is the strain of Brachyspira hyodysenteriae deposited at the Collection Nationale de Cultures de Microrganismes (CNCM), Institut Pasteur under the registration number CNCM I-4720, wherein the Brachyspira hyodysenteriae strain is inactivated.
US Pat. No. 10,188,716

PROTECTIVE ANTIGEN COMPLEXES WITH INCREASED STABILITY AND USES THEREOF

Wichita State University,...

1. A method for inducing an immunogenic response in a subject against B. anthracis, said method comprising administering to the subject a therapeutically-effective amount of an immunogenic composition against Bacillus anthracis, said composition comprising a stabilized protective antigen complex, said complex comprising Bacillus anthracis protective antigen protein and capillary morphogenesis protein-2, wherein said capillary morphogenesis protein-2 is bound to said protective antigen protein along a binding interface.
US Pat. No. 10,188,717

VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE

Genocea Biosciences, Inc....

1. A method for treating a subject suffering from or susceptible to Streptococcus pneumoniae infection, comprising administering an effective amount of a vaccine formulation comprising:(1) a first isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 265; and
(2) a second isolated polypeptide comprising:
(a) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 10, or
(b) an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.
US Pat. No. 10,189,742

GLASS FIBER, COMPOSITION FOR PRODUCING THE SAME, AND COMPOSITE MATERIAL COMPRISING THE SAME

JUSHI GROUP CO., LTD., T...


wherein
a weight percentage ratio of CaO/MgO is greater than 2 and less than or equal to 2.6; and
a weight percentage ratio SiO2/CaO is 3.3-4.3.
US Pat. No. 10,188,719

CONJUGATION OF STREPTOCOCCAL CAPSULAR SACCHARIDES

GLAXOSMITHKLINE BIOLOGICA...

1. A process for preparing a conjugate of a Streptococcus agalactiae capsular saccharide and a carrier molecule, comprising the steps of:(a) oxidising a S. agalactiae capsular saccharide in order to introduce an aldehyde group into at least one terminal sialic acid residue in the saccharide;
(b) subjecting the aldehyde group to reductive amination with ammonia or a primary amine, to give a —CH2-linked amine;
(c) reacting the —CH2-linked amine with a bifunctional linker, to give an activated saccharide; and
(d) reacting the activated saccharide with a carrier molecule, thereby giving the conjugate.
US Pat. No. 10,190,001

IR REFLECTIVE SURFACE TREATMENT

1. A water-based IR reflecting surface treatment composition of the following compounds:a base comprising:
a. 30 to 60% by weight of an acrylic resin;
b. 1 to 10% by weight of an alkyd resin;
c. 0.1 to 2% by weight of a polyolefin;
d. 0.1 to 1% by weight of an ammonium salt, wherein the ammonium salt comprises a carboxylated acrylic polymers;
e. Less than 0.1% by weight of a preservative;
f. Water such that base reaches 100% by weight; and
a paste comprising:
i. metal oxides having-a mean particle size between 0.05 and 5 ?m;
ii. a polymeric binder; and
wherein the water-based IR reflecting surface treatment composition is applied to an exterior surface of a building.
US Pat. No. 10,188,720

RECOMBINANT MAREK'S DISEASE VIRUSES AND USES THEREOF

CEVA SANTE ANIMALE, Libo...

1. A recombinant Marek's disease virus of serotype 1 (MDV1) which comprises (1) a promoter of 274 nucleotides in length consisting of SEQ ID NO: 5 or consisting of a sequence having at least 90% sequence identity to SEQ ID NO: 5 and exhibiting transcriptional promoter activity and (2) under the control of said promoter, a recombinant nucleotide sequence encoding a polypeptide.
US Pat. No. 10,190,002

AQUEOUS MULTI-STAGE EMULSION COPOLYMER COMPOSITIONS FOR USE IN JOINERY APPLICATIONS

Rohm and Haas Company, P...

1. An aqueous composition comprising aqueous multistage emulsion copolymer compositions comprising (a) one or more dihydrazide compounds in a total amount of from 0.5 to 4 wt. %, based on the total weight of composition solids, and (b) of one or more aqueous multistage emulsion copolymers containing, as (i) a first stage, an emulsion copolymer having a glass transition temperature (Tg) via differential scanning calorimetry (DSC) of from ?50 to 30° C., and containing, in copolymerized form, from 0.5 to 3.0 wt. % of one or more monoethylenically unsaturated phosphorous acid monomers and, from 0.75 to 5 wt. % of one or more keto group containing amide monomers, and, as (ii) a second stage, an emulsion copolymer having a DSC Tg of from 50° C. to 125° C., wherein the Tg difference between the first stage and the second stage is from 45° C. to 150° C. having a weight ratio of (i) the first stage to (ii) the second stage, based on copolymer solids, ranging from 50:50 to 90:10 or, all monomer wt. % s based on the total weight of monomers used to make the aqueous multistage emulsion copolymer, and, further wherein, the (ii) second stage of the aqueous multistage emulsion copolymer comprises, in copolymerized form, no more than 25 wt. % of the total monoethylenically unsaturated phosphorous acid monomers used to make the aqueous multistage emulsion copolymer, and no more than 50 wt. % of the total keto group containing amide monomers used to make the aqueous multistage emulsion copolymer, and wherein (b) at least one of the one or more aqueous multistage emulsion copolymer comprises, in copolymerized form, at least 90 wt. % of the one or more monoethylenically unsaturated phosphorous acid monomers in the (i) first stage.
US Pat. No. 10,190,003

DEGRADATION-RESISTANT SCALE INHIBITORS

Cytec Industries Inc., , ...

1. A method of reducing aluminosilicate containing scale in a Bayer process, comprising:identifying a Bayer process equipment surface that is subject to scale formation during the Bayer process;
contacting the identified Bayer process equipment surface with an amount of a scale inhibiting composition effective to form a treated surface that is more resistant to scale formation upon subsequent contact with a Bayer process stream than an otherwise comparable untreated surface; and
contacting the treated surface with the Bayer process stream;
wherein the scale inhibiting composition comprises a liquor comprising an aqueous solution of one or more water-soluble salts having at least about 0.004% by weight of total dissolved salts and a silicon-containing compound,
wherein the silicon-containing compound is resistant to degradation in alumina recovery process streams at process temperatures from about 100° C. to about 265° C.,
wherein the silicon-containing compound is a reaction product of at least a polyamine, a first nitrogen-reactive compound and a second nitrogen-reactive compound,
wherein:
the first nitrogen-reactive compound comprises a —Si(OR1b)3 group and a nitrogen-reactive group, where R1b is H, optionally substituted C1-C20 alkyl, optionally substituted C6-C12 aryl, optionally substituted C7-C20 aralkyl, optionally substituted C2-C20 alkenyl, Group I metal ion, Group II metal ion, or NR2b4, each R2b being independently selected from H, optionally substituted C1-C20 alkyl, optionally substituted C6-C12 aryl, optionally substituted C7-C20 aralkyl, or optionally substituted C2-C20 alkenyl;
the second nitrogen-reactive compound comprises a nitrogen-reactive group and does not contain a —Si(OR1b)3 group, and
wherein the silicon-containing compound is free of ?-hydroxy ether groups.
US Pat. No. 10,188,722

LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT

Aviex Technologies LLC, ...

1. A live genetically engineered Salmonella bacterium, having:a first loss-of-function mutation of the MsbB gene; and
a second loss-of-function mutation of the zwf gene,
being further genetically engineered to express at least one heterologous protein comprising an antigen adapted to act as a vaccine in a mammalian host,
wherein the live genetically engineered Salmonella bacterium having the first loss of gene function mutation and the second loss of gene function mutation has resistance to CO2, osmolarity and acidic pH, and reduced TNF-? induction capacity in the mammalian host after administration of a pharmaceutical dosage form containing the live genetically engineered Salmonella bacterium, relative to a wild type Salmonella bacterium of the respective live genetically engineered Salmonella bacterium having the first loss of gene function mutation of MsbB and not the second loss of gene function of zwf.
US Pat. No. 10,188,723

FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPS)

NOVAVAX, INC., Gaithersb...

1. A vaccine comprising an influenza VLP, wherein said VLP comprises influenza proteins, wherein the influenza proteins consist of M1, HA and NA proteins; wherein the M1 protein is derived from a different influenza virus strain than the HA and NA proteins; wherein the influenza proteins are insect-cell expressed, and wherein the M1 protein is from an avian influenza strain.
US Pat. No. 10,189,748

HEAT MOLDABLE CERAMIC COMPOSITION

DOW GLOBAL TECHNOLOGIES L...

1. A heat moldable composition comprisingan inorganic material that sets as a result of baking or sintering, and
a hydroxypropyl methylcellulose having a DS of at least 1.4 and a MS of at least 0.6, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxypropoxyl groups, and a viscosity of up to 80 mPa·s, determined as a 2% by weight solution in water at 20° C.,
wherein the heat moldable composition comprises at least 40 weight percent of the inorganic material and at least 10 weight percent of the hydroxypropyl methylcellulose, and
wherein the composition does not comprise more than 5 weight percent of water, all percentages being based on the total weight of the composition.
US Pat. No. 10,190,005

PAINTS, LACQUERS OR OTHER COATING MATERIALS WITH ANTI-PINHOLE ADDITIVE AND THE MANUFACTURE AND USE THEREOF

Hemmelrath Technologies G...

1. A process for applying a coating, which is in the form of a paint, a lacquer, or another coating material in a liquid solution, to a workpiece in order to obtain a pinhole-free surface, the method comprising:providing an anti-pinhole additive comprising hydrophilic pyrogenic silica;
determining whether the workpiece has been contaminated by silane or silanol compounds;
adding the anti-pinhole additive to the coating when the workpiece is determined to be contaminated by silane or silanol compounds; and
applying the coating to the surface of the workpiece.
US Pat. No. 10,190,261

STRENGTHENING RESINS FOR PAPER PRODUCTS

ECOLAB USA INC., St. Pau...

1. A fiber mixture, comprising:a plurality of fibers; and
a resin composition comprising:
about 10 wt % to about 80 wt % of a polyamide-epihalohydrin resin comprising a reaction product of a polyamidoamine and an epihalohydrin;
about 10 wt % to about 80 wt % of a cationic styrene maleimide resin comprising a reaction product of a styrene maleic anhydride copolymer and an amine compound; and
about 10 wt % to about 80 wt % of a urea-formaldehyde resin, wherein the weight percent values of the polyamide-epihalohydrin resin, the cationic styrene maleimide resin, and the urea-formaldehyde resin are based on a combined solids weight of the polyamide-epihalohydrin resin, the cationic styrene maleimide resin, and the urea-formaldehyde resin.
US Pat. No. 10,188,724

EFFICIENT MUCOSAL VACCINATION MEDIATED BY THE NEONATAL FC RECEPTOR

University of Maryland, C...

1. A composition comprising a fusion protein comprising an Fc fragment of an immunoglobulin recognized by neonatal receptors (FcRn), wherein the Fc fragment is fused at its amino terminal end to a desired antigen, wherein the Fc fragment comprises the hinge region, a CH2 domain and a CH3 domain of the immunoglobulin, wherein C1q motif has been mutated such that it renders the fragment non-lytic, and wherein there is a linker between the hinge region and the antigen, and wherein the antigen is selected from the group of antigens consisting of antigens from viruses, bacteria, parasites, and fungi, wherein said composition is administered to a mucosal epithelium and induces in said subject the formation of memory lymphocytes specific for said antigen.
US Pat. No. 10,189,749

HUMIC ACID LIGNITE COAL BASED LIQUID FERTILIZER

Innovative Crop Solutions...

1. A fertilizer composition prepared by a process comprising:(a) preparing a mixture consisting essentially of liquid nitrogen and lignite;
(b) mixing the liquid nitrogen and lignite;
(c) adding phosphoric acid to the mixture;
(d) mixing the phosphoric acid with the mixture;
(e) adding water to the mixture and phosphoric acid to form a solution;
(f) mixing the water with the solution;
(g) adding potash to the solution;
(h) mixing the potash into the solution;
(i) filtering the solution, wherein filtering is performed by gravity filtration; and
(j) placing the solution into a container.
US Pat. No. 10,189,750

FERTILIZER COMPOSITIONS COMPRISING A CELLULOSE NUTRIENT COMPONENT AND METHODS FOR USING SAME

1. A kit comprising:a) a cellulose nutrient component;
b) a microbial blend component;
c) a source of nitrogen;
d) a source of phosphorus;
e) exotic micronutrients;
f) binder; and
g) instructions for mixing and pelletizing components a)-f) to produce a pelletized fertilizer composition.
US Pat. No. 10,188,726

SYNTHETIC HEPATITIS C POLYPEPTIDE AND METHODS OF MAKING AND USING SAME

The Johns Hopkins Univers...

1. The polypeptide encoded by a nucleic acid comprising SEQ ID NO: 1, encoding the genome of the synthetic hepatitis C virus subtype 1a (Bole 1a).
US Pat. No. 10,191,032

METHOD OF DETECTION AND TREATMENT OF CLINICALLY SIGNIFICANT POST-PRANDIAL HYPERGLYCEMIA IN NORMOGLYCEMIC PATIENTS

True Health IP LLC, Fris...

1. A method of treating post-prandial hyperglycemia in a patient having impaired first-phase insulin response comprising:a. measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient;
b. comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and
c administering to the patient a diabetes therapy if the level of AHB in the single fasting baseline biological sample is determined to be at least 6.0 ?g/mL.
US Pat. No. 10,191,033

BIOMARKERS FOR DETECTING PRE-CACHEXIA OR CACHEXIA AND METHODS OF TREATMENT THEREOF

The Broad Institute, Inc....

1. A method of treating pre-cachexia in a subject who has cancer, a pre-cancerous condition, disease, age-related weight loss, or age-related sarcopenia; inhibiting the progression of pre-cachexia to cachexia in a subject who has cancer, a pre-cancerous condition, disease, age-related weight loss, or age-related sarcopenia; or treating or preventing undesirable muscle or fat loss in a subject who has cancer, a pre-cancerous condition, disease age-related weight loss, or age-related sarcopenia, the method comprising administering to the subject an effective amount of an agent that is:an ERK1/2 inhibitor selected from the group consisting of SCH772984, ARRY162, AS703026, AZD6244, AZD8330, BIX02188, BIX02189, honokiol, lenalidomide, PD98059, PD184352, PD325901, PD318088, RDEA119, SCH772984, SL-327, TAK733, trametinib (GSK1120212), U0126, and Vx-11e;
wherein, prior to treatment, a protein marker signature is detected in a biological sample obtained from the subject by detecting in the sample an alteration in at least three markers selected from the group consisting of S100A2 or S100A4; S100A8 or S100A9; and S100A7 relative to a reference;
detecting in the sample an alteration in at least four markers selected from the group consisting of: S100A2 or S100A4; S100A8 or S100A9; S100A7 and S100A14 relative to a reference; or
measuring the levels of at least five markers selected from the group consisting of S100A2 or S100A4; S100A8 or S100A9; S100A7; S100A14 and S100P in the sample.
US Pat. No. 10,188,984

PROCESS FOR REMOVING OXIDISABLE GASEOUS COMPOUNDS FROM A GAS MIXTURE BY MEANS OF A PLATINUM-CONTAINING OXIDATION CATALYST

1. A process for catalytic oxidative removal of at least one oxidisable gaseous compound from a gas mixture, the gas mixture comprising the at least one oxidisable gaseous compound as well as oxygen, the process comprising:reacting H2Pt(OH)6 with oxalic acid in an aqueous solution to form platinum oxalate complexes of the formula (H3O)1.6[Pt(C2O4)2]. 2H2O;
forming an oxidation catalyst by adding the platinum oxalate complexes to a porous catalyst support and exothermically decomposing the platinum oxalate complexes to generate catalytically active platinum species; and
oxidizing the gas mixture with the oxidation catalyst, wherein
the gas mixture is not a combustion flue gas.
US Pat. No. 10,191,034

DOSAGE REGIMEN FOR ADMINISTRATING A CD19×CD3 BISPECIFIC ANTIBODY TO PATIENTS AT RISK FOR POTENTIAL ADVERSE EFFECTS

AMGEN RESEARCH (MUNICH) G...

1. A method for treating a human patient suffering from malignant CD19-positive lymphoma or leukemia, wherein the patient is at risk for potential adverse effects resulting from treatment with a CD19×CD3 bispecific antibody comprising an amino acid sequence encoded by the nucleic acid sequence set forth in SEQ ID NO: 2 or the amino acid sequence set forth in SEQ ID NO: 1, the method comprising:(a) determining in the peripheral blood of the patient a ratio of B cells to T cells and total B cell count; and
(b) identifying the patient at risk as comprising a ratio of B cells to T cells of about 1:8 or lower;
(i) wherein a total B cell count of less than 40 B cells per microliter of peripheral blood is indicative of a higher risk for potential adverse effects for said patient; and
(ii) wherein a total B cell count of 40 B cells or greater per microliter of peripheral blood is indicative of a lower risk of potential adverse effects for said patient,
(c) administering the CD19×CD3 bispecific antibody
(i) to the patient who is at higher risk in an incremental dosage schedule to reduce the possibility of potential adverse effects in the patient,
wherein a first dose is administered for a first period of time and a second dose is consecutively administered for a second period of time,
wherein said second dose is greater than said first dose, and
wherein said second period of time exceeds said first period of time; or
(ii) to the patient who is at lower risk in a constant dose for at least four weeks.
US Pat. No. 10,188,729

MODULATION OF TUMOR IMMUNITY

1. A method of treating a tumor in a patient comprising administering to the patient a bispecific antibody comprising(i) a first arm having a light chain (LC) variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence of the LC variable region of MK-3475 and a heavy chain (HC) variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence of the HC variable region of MK-3475; and
(ii) a second arm having an LC variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence set forth in SEQ ID NO: 82 wherein residue 31 is Q and residue 57 is Q; and an HC variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence set forth in SEQ ID NO: 81.
US Pat. No. 10,188,730

ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

1. An antibody or antigen-binding fragment thereof that specifically binds human LAG3 comprising:a light chain variable domain comprising:
CDR-L1 that comprises the amino acid sequence: KASQSLDYEGDSDMN (SEQ ID NO: 38);
CDR-L2 that comprises the amino acid sequence: GASNLES (SEQ ID NO: 39); and
CDR-L3 that comprises the amino acid sequence: QQSTEDPRT (SEQ ID NO: 40); and
a heavy chain variable domain comprising:
CDR-H1 that comprises the amino acid sequence: DYNVD (SEQ ID NO: 33);
CDR-H2 that comprises the amino acid sequence: DINPNDGGTIYAQKFQE (SEQ ID NO: 457); and
CDR-H3 that comprises the amino acid sequence: NYRWFGAMDH (SEQ ID NO: 35).
US Pat. No. 10,188,731

METHODS FOR KILLING CANCER CELLS AND CELLULAR IMAGING USING MAGNETO-ELECTRIC NANO-PARTICLES AND EXTERNAL MAGNETIC FIELD

Ping Liang, Newport Coas...

1. A method for achieving high-specificity killing of targeted cells comprisingadministering manufactured Magneto-Electric Nano-Particles (MENPs) that are not loaded with a drug intended for killing targeted cells into a patient's body, wherein the MENPs generate an electric field when subjected to a magnetic field due to magnetic-electric coupling from correlated magnetostrictive and piezoelectric effects of their nanostructures and have a higher tendency to accumulate near or attach to targeted cells through one or more physical forces; and
after an amount of MENPs have come into sufficient proximity of, attached to or penetrated through the targeted cells' membrane, applying a magnetic field to the MENPs to generate an electric field via the MENPs which is sufficient to cause death of the targeted cells.
US Pat. No. 10,188,987

MULTIFUNCTIONAL FILTERS FOR DIESEL EMISSION CONTROL

BASF Corporation, Florha...

1. A catalyzed particulate filter comprising:a plurality of porous walls extending longitudinally to form a plurality of parallel passages extending from an inlet end to an outlet end, wherein a quantity of the passages are inlet passages that are open at the inlet end and closed at the outlet end, and a quantity of passages are outlet passages that are closed at the inlet end and open at the outlet end;
at least three coatings creating at least two zones axially along the plurality of porous walls, wherein a first coating is a first SCR catalyst coating, a second coating is a second SCR catalyst coating, and a third coating is a platinum group metal coating.
US Pat. No. 10,189,756

ADIABATIC PLUG FLOW REACTORS AND PROCESSES INCORPORATING THE SAME

BLUE CUBE IP LLC, Clayto...

1. A process for producing a chlorinated and/or fluorinated propene, having the formula CH2-c-gClcFg=CH1-d-hCldFh-CH3-e-fCleFf wherein c is 0-2, d is 0-1, e is 0-3, f is 0-3, g is 0-2 and h is 0-1, while c+g?2, d+h?1, and e+f?3 which process comprises providing a feed comprising methanes, chloromethanes, fluoromethanes, or chlorofluoromethanes, having the formula CH4-a-bClaFb, wherein each a and b are independently 0-3 and 4-a-b is greater than 0, and a chloroethylene or chlorofluoroethylene in an adiabatic plug flow reactor wherein the reactor is operably disposed relative to a mixer having a diameter and shape that are the same as those of the reactor, the reactants flow through the mixer, and the reactor further comprises a collector having the same shape and/or diameter as the reactor; wherein a turbulence flow region exists within at least a portion of the reactor having a Reynolds number (Re) of at least 2100, wherein the adiabatic plug flow reactor further comprises at least one of i) an insulation material, ii) a temperature controller for the reactor effluent; or iii) one or more temperature and flow controllers for one or more reactants, initiator(s) and/or diluents; wherein the reactor provides reduced backmixing and/or recirculation prior to entry into, or upon exit from, the reactor.
US Pat. No. 10,188,732

METHODS AND COMPOSITIONS FOR INACTIVATING ENVELOPED VIRUSES

Biogen MA Inc., Cambridg...

1. A method of inactivating an enveloped virus in a recombinant protein preparation, the method comprising contacting a recombinant protein preparation that comprises a recombinant protein with N,N-dimethyldodecyclamine N-oxide (LDAO) in an amount sufficient to inactivate the enveloped virus, wherein the amount is at a concentration above critical micelle concentration of the LDAO and does not inhibit biological activity of the recombinant protein.
US Pat. No. 10,188,988

CLAUS UNIT TREATMENT OF SHUTDOWN TAIL GAS

EXXONMOBIL RESEARCH AND E...

1. A method for regenerating a Claus unit in a sulfur removal complex comprising a plurality of Claus units and a smaller number of tail gas treating units (TGTUs), the method comprising the steps of:(a) switching a feed to a regenerating Claus unit's reaction furnace to natural gas;
(b) combusting the natural gas in the reaction furnace using an approximately stoichiometric amount of oxygen;
(c) sending tail gas from the regenerating Claus unit to an in-service TGTU;
(d) once liquid sulfur is no longer produced from the regenerating Claus unit in step (b), sending the tail gas to an in-service Claus unit's reaction furnace; and
(e) adding excess oxygen to the regenerating Claus unit's reaction furnace.
US Pat. No. 10,189,757

CHROMIA BASED FLUORINATION CATALYST

Mexichem Amanco Holding S...

1. A chromia-based fluorination catalyst consisting of:amorphous chromia;
zinc oxide in a total amount of zinc of from 0.5 to 25% by weight of the catalyst; and
crystalline chromium oxide in a total amount of from 0.1 to 2.5% by weight of the catalyst;
which catalyst is supported or unsupported.
US Pat. No. 10,190,014

SURFACE-TREATING AGENT FOR VULCANIZED RUBBER

NOK Corporation, Tokyo (...

1. A surface-treating agent for vulcanized rubber wherein the surface-treating agent comprises, based on 100 parts by weight, as solid matters, of isocyanate group-containing 1,2-polybutadiene, an organic solvent solution containing 10 to 160 parts by weight of fluororesin particles and 2.5 to 20 parts by weight of a perfluoroalkyl group-containing oligomer-based, fluorine-containing surfactant as a dispersant, and further comprises, based on 100 parts by weight, as solid matters, of the isocyanate group-containing 1,2-polybutadiene, 100 parts by weight or less, as solid matters, of a composition solution of an OH group-containing fluororesin composition having the following formulation:[I] a copolymer of
(A) a perfluoroalkylalkyl (meth)acrylate and
(B) a hydroxyl group-containing (meth)acrylate,
[II] a polymer of an acrylic acid alkyl ester,
[III] a polymer of a fluorinated olefin, and
[IV] a curing agent; and/or
60 parts by weight or less of silicone oil having a viscosity of 8,000 cs or more.
US Pat. No. 10,191,038

IMMUNOLOGICAL MEASURING METHOD AND MEASURING KIT FOR WHOLE BLOOD SAMPLE

LSI MEDIENCE CORPORATION,...

1. A method of measuring a target substance, comprising:providing a sample suspected of containing the target substance, or a solution derived from the sample, a first reaction solution, and a second reaction solution;
aspirating the sample or the solution derived therefrom, and the first reaction solution, using a measuring apparatus equipped with a dispensing unit, sequentially in this order into the dispensing unit;
discharging the sample or the solution derived therefrom, and the first reaction solution at the same time from the dispensing unit, to bring the sample or the solution derived therefrom, and the first reaction solution into contact with the second reaction solution, and to form a complex of the target substance, a first partner which is contained in the first reaction solution and reacts specifically with the target substance, and a second partner which is contained in the second reaction solution and reacts specifically with the target substance; and
analyzing the complex, or a signal derived from the complex, wherein
the specific gravity of the first reaction solution is higher than the specific gravity of the sample or the solution derived therefrom;
the sample or the solution derived therefrom and the first reaction solution are aspirated into the dispensing unit in an overlaid state; and
the first partner, which is contained in the first reaction solution and reacts specifically with the target substance, is labeled with a labeling substance, and the second partner, which is contained in the second reaction solution and reacts specifically with the target substance, is immobilized on a solid-phase carrier selected from the group consisting of beads, magnetic particles, and latex particles.
US Pat. No. 10,188,733

VACCINES COMPRISING BISPHOSPHONATE AND METHODS OF USE THEREOF

President and Fellows of ...

1. A method for stimulating an immune response to at least one viral immunogen in a human subject, comprisingadministering to the subject a single dose of about 0.001 mg to about 5.0 mg of a bisphosphonate to stimulate an immune response to the at least one viral immunogen in the subject,
wherein the bisphosphonate is free bisphosphonate and is not provided as a component of a particle delivery system, and
wherein the at least one viral immunogen and the bisphosphonate contact a population of naïve B cells in the subject and directly stimulate B cells to produce a neutralizing antibody specific to the at least one viral immunogen,
thereby stimulating an immune response to the at least one viral immunogen in the subject.
US Pat. No. 10,191,039

HUMAN FACTOR XIII AS A NORMALIZATION CONTROL FOR IMMUNOASSAYS

Bio-Rad Laboratories, Inc...

1. A kit for correcting for variations in sample processing and/or biological matrix effects when performing biological assays, said kit comprising human blood coagulation Factor XIII (hFXIII) immobilized on a solid support, anda plurality of solid supports having binding members immobilize thereon that bind an analyte in a sample, wherein the plurality of solid supports are divided into subpopulations that are differentiable from each other by a differentiation parameter comprising a characteristic that is independent of the binding members immobilized on the solid supports, and the binding members immobilized on each subpopulation are capable of binding to one analyte in the sample,
wherein the solid support and/or the plurality of solid supports is selected from the wall or floor of an assay vessel, a dipstick, particles inside or suspended in an assay vessel, a bead, a magnetic bead, or a microparticle formed of a polymeric material.
US Pat. No. 10,190,016

TWO-COMPONENT PAINT COMPOSITION AND MULTILAYER COATING FORMATION METHOD USING THIS

BASF Coatings GmbH, Muen...

1. A two-component paint composition, comprising (A) a base resin and (B) a curing agent,wherein,
the base resin (A) comprises a hydroxy group-containing acrylic resin (A-1) and a curing catalyst (A-2);
the curing agent (B) comprises an isocyanate compound (B-1) and an alkoxysilyl group-containing copolymer (B-2);
the hydroxy group-containing acrylic resin (A-1) has a hydroxyl value of 80 to 180 mg KOH/g, a glass transition temperature of ?40 to 40° C. and a weight average molecular weight of 2,000 to 20,000 g/mol; and
the alkoxysilyl group-containing copolymer (B-2) is a copolymer obtained by copolymerizing 30 to 80 parts by weight of a vinylic monomer comprising alkoxy-silyl groups and 20 to 70 parts by weight of other copolymerizable monomers, its weight average molecular weight is 2,000 to 20,000 g/mol, and it does not contain hydroxy groups, carboxyl groups amino groups which react with isocyanate groups.
US Pat. No. 10,191,040

METHOD OF MULTIPLEX IMMUNOASSAYS UTILIZING DIFFERENTIAL AFFINITY AND METHODS FOR SYNTHESIZING APTAMER-BASED REAGENTS FOR MULTIPLEX IMMUNOASSAYS

1. A method of selecting aptamers, wherein each selected aptamer can bind to a plurality of different target analytes (i), comprising:a) providing a library of oligonucleotides with random nucleotide sequences denoted a random sequence library and heating and quenching the random sequence library to incude the formation of the secondary structure;
b) preparing a plurality of magnetic particles conjugated with negative samples (j) (NS-MPs(j)), wherein the magnetic particles (MPs) are nanoparticles (MNPs) or microparticles (MMPs), and wherein j is a variable integer with a value from 1 to J and each type of J types of negative samples (j) is a different type of negative sample from the others;
c) incubating the random sequence library, from step a) if j equals one or from step d) of the preceding round if j is greater than one, with the NS-MPs(j) in a first binding buffer, wherein the random sequence library is incubated with each different NS-MPs(j) one by one, or the random sequence library is incubated with all of the different NS-MPs(j) in one batch, to allow oligonucleotides to bind to the NS-MPs(j);
d) removing oligonucleotides bound to the NS-MPs(j) by performing a first magnetic separation using a magnetic stand and collecting a supernatant containing oligonucleotides not bound to the NS-MPs(j) for step e) if j equals J or as a random sequence library for step c) of a following round if j is less than J, wherein the process steps c) and d) are performed J times if in step c) the random sequence library is incubated with the different NS-MPs(j) one by one and j increases with an increment of one for a following round during repetition or if in step c) the random sequence library is incubated with all of the different NS-MPs(j) in one batch, the process steps c) and d) are performed once;
e) preparing a plurality of magnetic particles conjugated with target analytes (i) (PS-MPs(i) and incubating the supernatant containing oligonucleotides, from step d) if i equals one or from step i) of the preceding round if i is greater than one, with the PS-MPs(i) to form a bound mixture containing oligonucleotides bound to PS-MPs(i), wherein the magnetic particles (MPs) are MNPs or MMPs and i is a variable integer with a value from 1 to I;
f) collecting the bound mixture containing oligonucleotides bound to the PS-MPs(i) by performing a second magnetic separation using the magnetic stand, removing a supernatant containing oligonucleotides not bound to the PS-MPs(i), and redispersing the collected bound mixture containing oligonucleotides bound to the PS-MPs(i) in a second binding buffer;
g) subjecting the redispersed bound mixture obtained in step f) to a window-MARAS in a first oscillating magnetic field with a lower-bound frequency fiL and/or a lower-bound strength HiL to detach oligonucleotides with a first binding affinity toward the PS-MPs(i) from the PS-MPs(i), and then removing a supernatant containing the oligonucleotides detached from the PS-MPs(i) and collecting the remaining bound mixture containing oligonucleotides bound to the PS-MPs(i) by performing a third magnetic separation using the magnetic stand;
h) redispersing the collected bound mixture obtained in step g) in a third binding buffer;
i) subjecting the redispersed bound mixture obtained in step h) to a window-MARAS at a second oscillating magnetic field with an upper-bound frequency fiU and/or an upper bound strength HiU to detach oligonucleotides with a second binding affinity toward the PS-MPs(i) from the PS-MPs(i), and then collecting a supernatant containing the oligonucleotides with the second binding affinity toward the PS-MPs(i) for step j) if i equals I or for step e) of a following round if i is less than I and removing oligonucleotides bound to the PS-MPs(i) with a third binding affinity toward the PS-MPs(i) by performing a fourth magnetic separation using the magnetic stand,
wherein the process steps e)-i) are repeated as one round for I times or the process steps e)-i) are repeated as one round for (I-1) times and followed by performing the process steps e)-h) once, eluting the oligonucleotides having a binding affinity toward the PS-MPs(i) stronger than the first binding affinity toward the PS-MPs(i) out of the PS-MPs(i), collecting a supernatant containing the oligonucleotides having a binding affinity toward the PS-MPs(i) stronger than the first binding affinity toward the PS-MPs(i) for step j) by performing a fifth magnetic separation using the magnetic stand, wherein the second binding affinity is stronger than the first binding affinity and the third binding affinity is stronger than the second binding affinity, and wherein fiL j) obtaining oligonucleotides capable of conjugating with PS-MPs(i) that are aptamers that can bind to I types of different target analytes (i).
US Pat. No. 10,188,991

PERMSELECTIVE ASYMMETRIC MEMBRANES

GAMBRO LUNDIA AB, Lund (...

1. A semipermeable asymmetric membrane, wherein the membrane material comprises at least one polysulfone, poly-ethersulfone, or polyarylethersulfone; and a polyvinylpyrrolidone, wherein the polyvinylpyrrolidone consists essentially of a polyvinylpyrrolidone with a weight average molecular weight Mw of more than 1,700 kDa and less than 1,900 kDa and with a number average molecular weight Mn between about 340 kDa to about 390 kDa.
US Pat. No. 10,193,094

ORGANIC LIGHT-EMITTING DEVICE HAVING DELAYED FLUORESCENCE

Merck Patent GmbH, (DE)

1. An organic electroluminescent device comprisinganode,
cathode,
at least one emitting layer which comprises a luminescent organic compound E which has a difference between the energies of its S1 and T1 states of not greater than 0.15 eV, and
2, 3, 4 or 5 layers H each having a thickness of greater than 2 nm which are arranged between one emitting layer of said at least one emitting layer, which is closest to said anode, and said anode,
where the following conditions apply to each layer H:
a difference D between the HOMO energy level of a layer H and the HOMO energy level of the closest layer having a thickness of greater than 2 nm on a cathode side of this layer H must be less than or equal to 0.4 eV, and
each of the layers H comprises at least one triarylamino compound which is a small organic molecule,
with the proviso that, for layers whose HOMO energy level has a value of less than ?6.7 eV, the LUMO energy level for the said condition occurs instead of the HOMO energy level and wherein the emitting layer which comprises compound E additionally comprises one or more matrix materials, and in that compound E is an emitting compound and the energy of the T1 state of the matrix material of the emitting layer is at most 0.1 eV lower than the energy of the T1 state of compound E.
US Pat. No. 10,188,737

STABILIZED PHARMACEUTICAL COMPOSITION

ASTELLAS PHARMA INC., To...

1. A pharmaceutical composition, comprising 5-{[(3R)-1-acryloylpynolidin-3-yl]oxy}-6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-pyrazine-2-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutical additive having a difference in water activity value of 0.1 or more, wherein the difference in water activity value is the water activity value difference between said pharmaceutical additive after storage in the opened state and said pharmaceutical additive after storage in the sealed state, and wherein the pharmaceutical additive having a difference in water activity value of 0.1 or more is one member, or two or more members selected from the group consisting of dextran, dextrin, crystalline cellulose, corn starch, calcium carbonate, lactose hydrate, anhydrous dibasic calcium phosphate, and mannitol.
US Pat. No. 10,189,762

PROCESS FOR PURIFICATION AND SEPARATION OF CANNABINOIDS, FROM DRIED HEMP AND CANNABIS LEAVES

Orochem Technologies, Inc...

1. A process for the purification of cannabidiol (CBD) in a crude cannabis extract stream to provide at least one high purity cannabidiol product selected from the group consisting of a high purity cannabinoid oil stream, a phytocannabinoid rich oil, a solid CBD aggregate and mixtures thereof being essentially free of tetrahydrocannabinol, said process comprising:a) passing the crude cannabis extract stream comprising debris and small particles, cannabidiol, tetrahydrocannabinol, cannabidiolic acid, tetrahydrocannabinolic acid, other cannabinols, chlorophylls, color bodies, sugars and carbohydrates, lipids, plant waxes, impurities, and ethanol to a first filtration zone comprising a series of successive filters of decreasing pore size, starting at a pore size of 100 microns and reducing to about 10 microns in 3 or more stages to remove debris and small particles in a progressive filtration step to provide a filtered crude cannabinoid stream;
b) passing the filtered crude cannabinoid stream comprising cannabidiol, tetrahydrocannabinol, cannabidiolic acid, tetrahydrocannabinolic acid, other cannabinols, chlorophylls, color bodies, sugars and carbohydrates, lipids, plant waxes, impurities, and ethanol to a decolorization zone comprising a 10 ?m filter and a decolorization chromatographic column containing a modified activated carbon adsorbent which was heat treated to provide a highly hydrophobic adsorbent which is essentially free of hydroxyl groups, has an average particle diameter of between 177 and 250 microns, and an iodine number of above 900 mg/g and operated at a decolorization pressure of 2.72 atm to about 4.08 atm (40-60 psig) and a decolorization temperature ranging from 20-25° C. to remove at least a portion of color bodies and essentially all of the chlorophyll to provide a decolorized extract stream;
c) passing the decolorized extract stream to a first evaporation zone operated at a first vacuum pressure of ?0.60 to about ?0.74 atm (?18 to ?22 in Hg) and a temperature of about 90 to about 110° C. to remove at least a portion of the ethanol to provide an evaporated extract stream which is essentially free of ethanol;
d) passing the evaporated extract stream comprising cannabidiol (CBD), cannabidiolic acid (CBDA), tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), sugars and carbohydrates, lipids, plant waxes, impurities and other cannabinoids to an activation zone and therein subjected to a carboxylation reaction at a decarboxylation temperature of about 90 to about 120° C. and a decarboxylation pressure of about ?0.6 atm to 0.74 atm for a decarboxylation reaction time of about 5 to about 8 hours, or sufficient time for the decarboxylation reaction to occur and proceed to completion, said decarboxylation reaction time being sufficient to fully decarboxylate essentially all of the cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA) to provide a decarboxylated cannabinoid oil comprising cannabidiol (CBD), tetrahydrocannabinol (THC), lipids, plant waxes, and other cannabinoids, and being essentially free of cannabidiolic acid (CBDA) and tetrahydrocannabinolic acid (THCA), and water washing the decarboxylated cannabinoid oil to remove at least a portion of the impurities to provide a washed decarboxylated cannabinoid oil;
e) admixing the washed decarboxylated cannabinoid oil with a dewaxing solvent having a dewaxing solvent volume ratio of 80 volume units of ethanol to 20 volume units water to provide a dewaxing feed stream and passing the dewaxing feed stream to a dewaxing zone containing a dewaxing column at a dewaxing column pressure of about 2.72 atm to about 4.08 atm (40-60 psi) and room temperature (20-25° C.), said dewaxing column containing a hydrophobic activated carbon adsorbent which is essentially free of hydroxyl groups, and having an average particle diameter of between 177 and 250 microns, and an iodine number of above 900 mg/g to remove at least a portion of the lipids and plant waxes and to provide a dewaxed cannabinoid oil stream comprising cannabidiol (CBD), tetrahydrocannabinol (THC), sugars and carbohydrates, color bodies, and other cannabinoids;
f) passing the dewaxed cannabinoid oil stream and a mobile phase desorbent stream consisting of a mixture of food grade ethanol and water to a reversed phase simulated moving bed zone comprising a plurality of adsorbent beds containing a modified hydrophobic adsorbent comprising a styrene-divinylbenzene (DVB) resin having 4 to 8 percent crosslinking or a poly(methyl methacrylate) (PMMA) resin, said modified hydrophobic adsorbent having an average particle diameter of between 25 and 300 microns, an average bulk density (gm/mL) of from 0.4 to 0.6, a surface area (m2/g) of from 450 to 550, and a pore volume of from 0.70-0.90 (mL/g) to provide a primary raffinate stream comprising cannabidiol (CBD), mobile phase desorbent, sugars and carbohydrates, color bodies, and other cannabinoids and being essentially free of tetrahydrocannabinol (THC), an extract stream comprising mobile phase desorbent, cannabidiol (CBD), and tetrahydrocannabinol (THC), and a secondary raffinate stream comprising mobile phase desorbent, cannabidiol (CBD) which is admixed with the mobile phase desorbent and returned to the reversed phase simulated moving bed zone;
g) passing the primary raffinate to a second evaporation zone to remove mobile phase desorbent to provide a second recovered solvent stream comprising the mobile phase desorbent and to provide the high purity cannabinoid oil stream having an average cannabidiol purity of greater than 80 wt % and being essentially free of tetrahydrocannabinol (THC);
h) passing at least a portion of the high purity cannabinoid oil stream to a polishing zone and therein admixing the high purity cannabinoid oil stream with a non-polar solvent stream comprising hexane and therein allowing the admixture to settle to form a precipitate comprising sugars and carbohydrates and a supernatant non-polar solution comprising cannabidiol (CBD), color bodies, and other cannabinoids;
i) passing a portion of the supernatant non-polar solution to a second filtration zone to remove the precipitate and to provide a filtered supernatant non-polar solution;
j) passing the filtered supernatant non-polar solution to a third evaporation zone to remove at least a portion of the non-polar solvent to provide an evaporated cannabinoid oil stream and a recovered non-polar solvent stream, and returning at least a portion of the recovered non-polar solvent stream to the polishing zone to be admixed with the non-polar solvent;
k) passing the evaporated cannabinoid oil stream to a wash zone and alternately washing the evaporated cannabinoid oil stream first with an ethanol wash stream comprising pure ethanol in a washing ratio of 1:3 liters of ethanol to kilograms of evaporated cannabinoid oil, and second with a fourth water wash stream in a water wash ratio of 1:3 liters of water to kilograms of evaporated cannabinoid oil, and wherein following each step, washed cannabinoid oil is evaporated to dryness to provide a phytocannabinoid rich oil which is essentially free of tetrahydrocannabinol (THC) and comprising greater than 80 wt-% cannabinoid (CBD);
l) passing a portion of the supernatant non-polar solution to a isolate chromatography zone comprising a first isolate chromatography column and a second isolate chromatography column being in serial fluid communication and wherein the first isolate chromatography column contains a modified hydrophilic adsorbent comprising a spherical polar silica adsorbent having a high level of silenol groups, an average particle diameter of between 60 and 200 microns, a surface area of between 450 to 550 m2/g a pore volume of between 0.7 and 0.85 mL/g and a pore size of between 0.005 and 0.0075 microns, wherein the second isolate chromatography column contains an activated alumina adsorbent having an average particle diameter of between 50 to 200 microns, an average bulk density of 0.85 g/ml, a surface area of between 140 and 170 m2/g, and an average pore diameter of greater than 0.006 microns to provide an isolate elute stream comprising cannabidiol (CBD), non-polar solvent and other cannabinoids;
m) passing the isolate elute stream to a crystallization zone, wherein the isolate elute stream is subjected to a freezer temperature of equal to or less than about ?20° C. for a freezer period of about 24 to about 72 hours to permit primary high purity cannabidiol crystals, containing from about 96 to about 98 wt-% cannabidiol to form, harvesting the primary high purity cannabidiol (CBD) crystals and admixing the primary high purity cannabidiol crystals with hexane to provide the crystal isolate solution comprising 20-30% by weight cannabidiol CBD oils, and retaining the crystal isolate solution at room temperature for a period of 24-72 hours to permit secondary high purity CBD crystals to form and harvesting the secondary high purity CBD crystals;
n) passing the secondary high purity CBD crystals to a rotary evaporation zone wherein the secondary high purity crystals are heated until molten to evaporate any residual non-polar and washed with a third water wash stream at least three times in the rotary evaporation, wherein at the completion of each wash step the secondary high purity crystals are dried to complete dryness to provide a solid CBD aggregate which is essentially free of tetrahydrocannabinol (THC) and has a cannabidiol purity of greater than 99 wt-%; and,
o) withdrawing at least one high purity cannabidiol product being essentially free of tetrahydrocannabinol (THC) a stream selected from the group consisting of the high purity cannabinoid oil stream, the phytocannabinoid rich oil, the solid CBD aggregate and mixtures thereof.
US Pat. No. 10,190,019

MULTISTAGE POLYMERS AND COMPOSITIONS THEREOF

BASF SE, Ludwigshafen (D...

1. A multilayer particle comprising(i) a first layer comprising a first copolymer derived from a soft ethylenically-unsaturated monomer, a phosphorus-containing monomer, and an acetoacetoxy monomer; and
(ii) a second layer surrounding at least a portion of the first layer comprising a second polymer derived from at least 90% by weight of one or more hard ethylenically-unsaturated monomers selected from the group consisting of methyl methacrylate, styrene, and combinations thereof, based on the total weight of monomers used to form the second polymer;wherein the particle exhibits a single Tg, measured using DSC, ranging from ?10° C. to 25° C.
US Pat. No. 10,188,738

FORMULATIONS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES AFFECTING THE RESPIRATORY TRACT

1. A dry powder pharmaceutical formulation configured for administration by inhalation, comprising microparticles formed by at least one carrier and, embedded in the microparticles, nanoparticles comprising at least one antineoplastic agent and at least one folate receptor (FR)-targeting compound, wherein the at least one carrier comprises mannitol or dextran or mannitol and leucine, and wherein the at least one carrier is configured to allow for reconstitution of the nanoparticles when the microparticles are dissolved or dispersed in an aqueous medium.
US Pat. No. 10,190,020

SILOXANE-BASED COATINGS CONTAINING POLYMERS WITH UREA LINKAGES AND TERMINAL ALKOXYSILANES

The United States of Amer...

8. A composition comprising:an amine-functional compound or an epoxy- or acrylate-functional compound; and
a urea-containing composition made by a method comprising:
reacting an amino-functional alkoxysilane with a first polyisocyanate to form one or more adducts having an unreacted isocyanate group; and
reacting the adducts with one or more polyfunctional amino- and/or hydroxyl compounds and a second polyisocyanate to form the urea-containing composition;
wherein the urea-containing composition comprises at least two residues of the polyfunctional amino- and/or hydroxyl compounds;
wherein isocyanate groups do not react with other isocyanate groups; and
wherein the urea-containing composition contains no unreacted isocyanate groups;
wherein the urea-containing composition is characterized by any of:
a) at least one of the polyfunctional amino- and/or hydroxyl compounds comprises an amino group and at least one of the polyfunctional amino- and/or hydroxyl compounds comprises a hydroxyl group;
b) at least one of the polyfunctional amino- and/or hydroxyl compounds is a polyfunctional amino compound; and
c) the urea-containing composition comprises one of more compounds having the formula:
{[(R1O)aR13-aSi—(CH2)3—NR2—CO—NH]n—R3—NH—CO—X—R5—X—CO—NH}m—R3
wherein each a is independently selected from 1, 2, or 3;
wherein m is 2 or 3;
wherein each n is independently selected from 1 or 2;
wherein each X is independently selected from —NR4— and —O—;
wherein each R1 group is an independently selected alkyl group;
wherein each R2 and R4 is independently selected from hydrogen, aryl, alkyl, cycloalkyl, ester-containing aliphatic, ester-containing fluorinated aliphatic, amide-containing aliphatic, and polysiloxane;
wherein each R3 is an independently selected residue of an aliphatic, cycloaliphatic, or aromatic polyisocyanate having 2 or 3 isocyanate groups; and
wherein each R5 independently comprises a group selected from aliphatic, cycloaliphatic, aromatic, polyester, polyether, polysulfide, polyurethane, polycarbonate, polysiloxane, and any combination thereof moisture-curing the composition.
US Pat. No. 10,193,097

LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE

Semiconductor Energy Labo...

10. A light-emitting element comprising:a first electrode;
a hole-injecting layer over the first electrode
a hole-transporting layer over the hole-injecting layer;
a light-emitting layer over the hole-transporting layer;
an electron-transporting layer over the light-emitting layer;
an electron-injecting layer over the electron-transporting layer;
a second electrode over the electron-injecting layer;
a first layer between the hole-transporting layer and the light-emitting layer; and
a second layer between the light-emitting layer and the electron-transporting layer,
wherein:
the light-emitting layer includes a first phosphorescent compound,
the first layer includes a first hole-transporting material and a first electron-transporting material,
the second layer includes a second hole-transporting material and a second electron-transporting material,
the second hole-transporting material includes a second phosphorescent compound,
in the first layer, a concentration of the first hole-transporting material is higher than that of the first electron-transporting material,
in the second layer, a concentration of the second electron-transporting material is higher than that of the second hole-transporting material, and
a difference between a wavelength of a highest peak of an emission spectrum of the second phosphorescent compound and a wavelength of a highest peak of an emission spectrum of the first phosphorescent compound is within 30 nm.
US Pat. No. 10,188,739

COMPOSITIONS AND METHODS FOR ADMINISTERING INSULIN OR INSULIN-LIKE PROTEIN TO THE BRAIN

XENETIC BIOSCIENCES, INC....

1. A method of administering a therapeutically effective amount of an insulin to the brain of an individual, the method comprising intranasal administration of a pharmaceutical composition comprising a population of the insulin and/or an insulin-like protein attached to a polysialic acid where administration results in a therapeutically effective amount in the brain but not the serum of the individual.
US Pat. No. 10,189,764

HYDROGENATION OF OXYGENATED MOLECULES FROM BIOMASS REFINING

VIRDIA, INC., Raceland, ...

1. A method for producing 2-butanone and a conversion product, the method comprising:dehydrogenating 2-butanol to yield 2-butanone, thereby releasing hydrogen;
using hydrogen released from the dehydrogenating in a conversion reaction, wherein the conversion reaction converts a biomass-derived molecule to a conversion product; and
recovering 2-butanone and the conversion product.
US Pat. No. 10,191,045

SOL COMPOSITION FOR SOL-GEL BIOCHIP TO IMMOBILIZE PROBE ON SUBSTRATE WITHOUT SURFACE TREATMENT AND METHOD AND SCREENING THEREOF

So Youn Kim, Seoul (KR)

1. A method for screening a sol composition for sol-gel biochips, which is used to immobilize a probe on a surface-untreated substrate, the method comprising the steps of:(a) obtaining a first library of sol compositions wherein at least one silicate monomer selected from the group consisting of tetramethylorthosilicate (TMOS), methyltrimethoxysilane (MTMOS), tetraethylorthosilicate (TEOS), ethyltrimethoxysilane (ETrEOS), trimethoxysilane (TMS), methyltrimethoxysilicate (MTMS) and 3-aminopropyltrimethoxysilicate (3-ATMS), and at least one additive selected from the group consisting of polyglyceryl silicate (PGS), diglyceryl silane (DGS), 3-glycidoxypropyl trimethoxysilane (GPTMOS), (N-triethoxysilylpropyl)-0-polyethylene oxide urethane (PEOU), glycerol and polyethylene glycol (PEG) having a molecular weight of 100-10,000, are mixed with each other in buffer at various ratios;
(b) spotting the first library of sol compositions on a surface-untreated target substrate;
(c) measuring the adhesion, appearance, transmittance and gelling time of the spots formed in the step (b), and selecting, based on the measurement results, compositions, which do not show the detachment of spots even when they are scratched with a tip after washing, have a spot diameter of 100-800 ?m while maintaining a circular shape, show a self-fluorescence lower than background fluorescence, and have a gelling time of 4-48 hours in a tube and a gelling time of 1-4 hours on the spots of the substrate, thereby obtaining a second library of sol com positions;
(d) adding a probe to the second library of sol compositions and spotting the probe-containing second library on a surface-untreated substrate; and
(e) measuring the immobilization rate of the spots for the probe, and the specificity between the probe and a target substance, and selecting, based on the measurement results, a sol composition wherein the immobilization rate of the probe is at least 70% and the ratio of specific signals/non-specific signals of the probe and the target substance is at least 3.
US Pat. No. 10,188,740

MODIFIED FC MOLECULES

AMGEN INC., Thousand Oak...

1. A composition of matter comprising:(i) a monomeric or multimeric Fc domain having a cysteine or non-canonical amino acid substitution at one or more specifically selected conjugation site(s) selected from D46, S48, H49, E50, E53, K55, D61, G62, Q76, Y81, K107, K121, G122, Q123, E126, R136, D137, T140, K141, N142, E169, N170, N171, K173, L179, S181, G183, D194, K195, R197, Q199, Q200, G201, N202, or S223, relative to reference sequence SEQ ID NO:599; and
(ii) at least one additional functional moiety, wherein the functional moiety is conjugated to the Fc domain through the side chain of the cysteine residue or non-canonical amino acid residue substituted at said one or more conjugation site(s).
US Pat. No. 10,190,022

ANTIFOULING COMPOSITION, ANTIFOULING SHEET, AND METHOD FOR MANUFACTURING ANTIFOULING SHEET

LINTEC CORPORATION, Itab...

1. An antifouling composition comprising a polysilazane-based compound (A) and a both terminal carboxy-modified silicone (B),wherein a content of the silicone (B) is from 0.01 to 10 parts by mass based on 100 parts by mass of a total amount of the compound (A), and the antifouling composition is suitable for use as a sheet-like antifouling layer-forming material.
US Pat. No. 10,188,741

TARGETING OF INNATE IMMUNE RESPONSE TO TUMOR SITE

GAVISH-GALILEE BIO APPLIC...

1. A method of treatment of tumors, comprising administering to a patient in need microparticles or nanoparticles comprising:(i) a targeting agent to the tumor or the tumor environment, optionally biotinylated, wherein said targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor cells;
(ii) two or more inducers, optionally biotinylated, that stimulate an innate immune response in the tumor environment, leading to tumor apoptosis, selected from the group consisting of mannose, mannan, lipopolysaccharide (LPS), a Toll-like Receptor (TLR) ligand, N-formyl-methionyl-leucyl-phenylalanine (fMLF or fMLP), Complement 3a (C3a), Complement 5a (C5a), and a C, CC, CXC or CX3C chemokine,
wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles.
US Pat. No. 10,191,303

MULTIFOCAL BIMODULUS CONTACT LENSES

NexisVision, Inc., Menlo...

1. An ophthalmic lens for correcting presbyopia of an eye, the eye having a cornea characterized by a refractive shape extending across an optical region of the cornea, the ophthalmic lens comprising:an inner optic portion and a peripheral portion disposed radially outward of the inner optic portion, wherein,
the inner optic portion is configured to be disposed over the optical region of the cornea;
the inner optic portion is characterized by an inner rigidity and the peripheral portion is characterized by a peripheral rigidity;
the inner rigidity is greater than the peripheral rigidity; and
the inner rigidity is from about 1E8 MPa-?m3 to about 1E11 MPa-?m3; and
an anterior surface and a posterior surface opposite the anterior surface, wherein,
a portion of the anterior surface is configured to correct presbyopia; and
the posterior surface is configured to provide one or more lenticular volumes between the posterior surface and the optical region of the cornea.
US Pat. No. 10,188,742

BI-SPECIFIC ANTIBODIES AND USES THEREOF

KAOHSIUNG MEDICAL UNIVERS...

1. A humanized bi-specific antibody against the terminal methoxy or hydroxyl group of polyethylene glycol (PEG) and a target ligand, comprising,a first antigen binding site that binds to the PEG; and
a second antigen binding site that binds to the target ligand that is HER2;
wherein,
the first antigen binding site comprises the first VL-Ck domain consisting of SEQ ID NO: 12, the first VH-CH1 domain consisting of SEQ ID NO: 13, and the first HR-CH2-CH3 domain consisting of SEQ ID NO: 22; and
the second antigen binding site comprises a humanized single chain variable fragment (scFv) consisting of SEQ ID NO: 15.
US Pat. No. 10,189,767

PROCESS FOR MANUFACTURING SUCCINIC ACID FROM A FERMENTATION BROTH USING NANO FILTRATION TO PURIFY RECYCLED MOTHER LIQUOR

DSM IP ASSETS B.V., Heer...

1. A process for manufacturing succinic acid comprising:a) providing an aqueous solution of succinic acid;
b) crystallizing the succinic acid from the aqueous solution to form intermediate crystals and a mother liquor;
c) separating the intermediate crystals from the mother liquor;
d) treating the mother liquor by nanofiltration;
e) recycling the treated mother liquor to b);
f) purifying the intermediate crystals; and
g) recovering succinic acid.
US Pat. No. 10,190,024

POLISHING COMPOSITION

FUJIMI INCORPORATED, Kiy...

1. A polishing composition, comprising silica particles as abrasives and a basic compound as polishing removal accelerator, whereina density of silanol groups of the silica particles is 1.5 to 6.0 pieces/nm2,
an adsorption ratio parameter A of the polishing composition is 1.2 or less, the adsorption ratio parameter represents concentration dependency of an amount of adsorption of the basic compound to the silica particles as a ratio of high-concentration adsorption amount/low-concentration adsorption amount, and
the polishing composition has a pH of 8 to 12.
US Pat. No. 10,191,048

FLUOROMETRIC IMMUNOASSAY FOR DETECTION OF ANTI-DSDNA ANTIBODIES

1. A fluorometric immunoassay method for detecting antibodies against double-stranded DNA (anti-dsDNA), comprisingproviding decomplemented sera from a patient, providing isolated dsDNA as antigens from a source,
Precipitating immune complexes with a saturated solution of ammonium sulfate or solution of polyethylene glycol (PEG), wherein the immune complexes are a consequence of incubation of decomplemented patient's sera with the dsDNA,
separating the immune complexes into two samples,
labeling the samples by adding fluorescent dyes specific to the dsDNA to the samples, and
detecting of fluorescence in the samples, namely sample with supernatant and sample with precipitate, comprising immune complexes comprising dsDNA and anti-dsDNA,
wherein the detected fluorescence is a consequence of binding of fluorescent dyes into the dsDNA.
US Pat. No. 10,189,768

PROCESS FOR HYDROGENOLYSIS OF ALPHA-HYDROXY ESTERS OR ACIDS USING A HETEROGENEOUS CATALYST

Danmarks Tekniske Univers...

1. A method for hydrogenolysis of alpha-hydroxy esters or acids, comprising:reacting the alpha-hydroxy ester or acid in the presence of a solid catalyst and a catalyst support,
wherein the catalyst comprises at least two different metals that are Cr, Mn, Fe, Co, Ni, Cu, Zn, Mo, Ru, Rh, Pd, Ag, Cd, W, Re, Os, Ir, Pt, Au, or Hg, or a combination thereof, and
wherein the catalyst support is a porous solid material with the proviso that if the porous solid material consists of one metal oxide, the metal oxide is not SiO2.
US Pat. No. 10,191,049

SCREENING METHODS AND USES THEREOF

BioInvent International A...

1. A method of isolating at least one anti-ligand to at least one differentially-expressed target ligand, said method comprising the steps of:(a) performing differential biopanning on a library of anti-ligands so as to isolate at least one anti-ligand against said target ligand, wherein said differential biopanning comprises:
(i) providing a first population of ligands fixed to or incorporated in a subtractor ligand construct;
(ii) providing a second population of ligands comprising the same ligands as step (i), fixed to or incorporated in a target ligand construct;
(iii) determining an amount of said subtractor ligand construct and an amount of said target ligand construct so as to permit isolation of said at least one anti-ligand to said differentially-expressed target ligand;
(iv) exposing said library of anti-ligands to said amount of said subtractor ligand construct and said amount of said target ligand construct determined in step (iii) to permit binding of anti-ligands to ligands; and,
(v) isolating anti-ligands bound to said target ligand construct; and,
(b) performing next generation deep sequencing on anti-ligands isolated during step (a).
US Pat. No. 10,188,744

AMPHIPATHIC PEPTIDE

1. An amphipathic cell penetrating peptide of less than 50 amino acid residues comprising at least 6 arginine residues (R), at least 12 alanine residues (A), at least 6 leucine residues (L), optionally at least one cysteine residue (C) and at least two but no greater than three glutamic acids (E) whereinthe arginine (R) residues are evenly distributed along the length of the peptide;
the ratio of arginine (R) to negatively charged glutamic acid (E) residues is from at least 6:2 to 9:2; and
the ratio of hydrophilic amino acid residues to hydrophobic amino acid residues at pH 7 is at least 30:67 to 40:60; or
wherein the peptide comprises or consists of WEARLARALARALARELARALARALRACEA (SEQ ID No. 4).
US Pat. No. 10,189,769

METHOD FOR PREPARATION OF PHARMACEUTICALLY ACCEPTABLE CHLOROGENIC ACID

SICHUAN JIUZHANG BIOLOGIC...

1. A method for the preparation of pharmaceutically acceptable chlorogenic acid, comprising:a. extracting an extract containing chlorogenic acid from leaves of Eucommia ulmoides; treating the extract to obtain a sample having a concentration of chlorogenic acid of no less than 60% by weight;
b. dissolving the sample in purified water to obtain a first solution having a concentration of chlorogenic acid ranging from 20 mg/ml to 2000 mg/ml; and filtering the solution to obtain a filtrate and a filtride;
c. freezing the filtrate;
d. thawing the frozen filtrate and keeping the thawed filtrate at a temperature of above freezing to up to 5° C.;
e. dissolving a filtride in an organic solvent to obtain a second solution; filtering the second solution to obtain an organic solution, wherein the organic solvent is selected from the group consisting of methyl acetate, ethyl acetate, propyl acetate, and butyl acetate;
f. condensing the organic solution at an elevated temperature and under vacuum until forming a precipitant; resting the organic solution to form crystals in the organic solution; and
g. filtering crystals from the organic solution; drying the crystals under vacuum or standard pressure.
US Pat. No. 10,190,026

WOOD ADHESIVE

INDUSTRIAL TECHNOLOGY RES...

1. A wood adhesive, consisting of:a first agent, consisting of:
a sodium carboxymethyl cellulose having a molecular weight between 15,000 and 500,000 and a degree of substitution of from 0.4 and 2.00 of the sodium salt; and
a styrene-butadiene rubber polymer; and
a second agent, consisting of:
a polymeric quaternary amine and NaOH, wherein a ratio of the weight of the styrene-butadiene rubber polymer to the sum of weights of the sodium carboxymethyl cellulose and the polymeric quaternary amine is in the range from 0.05:1 to 1:0.1.
US Pat. No. 10,191,050

RATIONALE, METHODS, AND ASSAYS FOR IDENTIFYING HUMAN AND NON-HUMAN PRIMATE TASTE SPECIFIC GENES AND USE THEREOF IN TASTE MODULATOR AND THERAPEUTIC SCREENING ASSAYS

SENOMYX, INC., San Diego...

1. A method of identifying from a population of T1R expressing cells those which only express T1R3 and not T1R2 or T1R3 comprising (i) detecting whether said T1R expressing cells express LOC285965 and (ii) if positive identifying said cells as cells which express T1R3 and not T1R2 or T1R3.
US Pat. No. 10,189,770

PRODUCTION METHOD OF HIGHLY UNSATURATED FATTY ACID ETHYL ESTER

Bizen Chemical Co., Ltd.,...

1. A method of purifying highly unsaturated fatty acid derivatives from a mixture comprising highly unsaturated fatty acid derivatives, comprising a step selected from the group consisting of the following (1) to (4):(1) (a) providing the mixture having a peroxide value (POV) of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt;
(2) (a) providing the mixture having a peroxide value of 1 or smaller, wherein the peroxide value of the mixture is adjusted by a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt;
(3) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) contacting the mixture with an aqueous solution of silver salt; and
(4) (a) decreasing a peroxide value of the mixture to 1 or smaller by contacting the mixture with a POV reducing agent, and
(b) mixing the mixture with an aqueous solution of silver salt,
wherein the derivatives comprise at least one of a methyl ester, ethyl ester, amide, methyl amide, triglyceride, diglyceride or monoglyceride derivative.
US Pat. No. 10,190,027

HOT MELT ADHESIVE

1. A hot melt adhesive comprising:(A) 1-15 wt % of a polar functional group-modified conjugated diene-based polymer;
(B) 10-50 wt % of a butyral resin;
(C) 5-40 wt % of an olefin-based polymer;
(D) 5-70 wt % of a tackifier resin; and
(E) 10-40 wt % of a wax.
US Pat. No. 10,191,051

COMPOSITIONS AND METHODS FOR IMPROVED CELL-BASED BOTULINUM NEUROTOXIN ASSAYS

BIOMADISON, INC., Del Ma...

1. A method of increasing the sensitivity of cell-based detection of a botulinum toxin, comprising:(i) providing, in a first media having a sodium concentration greater than 65 mM, a transfected cell that produces a construct comprising;
(a) a terminus comprising a reporter-containing portion, wherein the reporter-containing portion exhibits a signal; and,
(b) a cleavage site that interacts with the botulinum toxin in a manner that produces a cleavage of the reporter-containing portion from a remainder of the construct;
(ii) transferring the transfected cell to a second media having a sodium concentration of less than 50 mM;
(iii) contacting the transfected cell with the botulinum toxin; and
(iv) obtaining the signal from the reporter-containing portion.
US Pat. No. 10,188,747

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

The General Hospital Corp...

1. A method of treating squamous cell carcinoma in a subject in need of treatment thereof, the method comprising administering to the subject an agonist of a gene selected from the group consisting of:Esr2; Dlx5; and Egr3.
US Pat. No. 10,189,772

MIXTURES OF CHELATING AGENTS INCLUDING AN L-ENANTIOMER-RICH MGDA, AND PROCESS FOR MAKING SUCH MIXTURES

BASF SE, Ludwigshafen (D...

1. A mixture, comprising:(A) 90 to 99.9% by weight of a mixture of L- and D-enantiomers of methyl glycine diacetic acid (MGDA) or its respective mono-, di- or trialkali metal or mono-, di- or triammonium salts, said mixture containing predominantly the respective L-enantiomer with an enantiomeric excess (ee) in the range of from 10 to 99%, and
(B) in total 0.1 to 10% by weight of a diacetic acid derivative of at least one amino acid selected from the group consisting of valine, leucine, isoleucine, and tyrosine, as free acids or respective mono-, di- or trialkali metal or mono-, di- or triammonium salts,
wherein the percentages refer to the sum from (A) and (B).
US Pat. No. 10,190,029

REMOVABLE POLYURETHANE HOT MELT ADHESIVE AND THE USE THEREOF

1. A removable reactive hot melt adhesive comprising a (meth)acrylate polymer and an isocyanate-functional polyurethane prepolymer, wherein the (meth)acrylate polymer has a number average molecular weight from about 25000 g/mol to about 60000 g/mol and is selected from a copolymerization product of butyl acrylate and methyl methacrylate as monomers having a melting point of from about 100° C. to about 120° C., a copolymerization product of butyl methacrylate and methyl methacrylate as monomers having a melting point about 110° C., and combinations thereof; andwherein the cured adhesive has a bond strength of about 5.0 MPa or greater at room temperature and a bond strength of about 0.8 MPa or less at a temperature of about 70° C. to about 90° C.
US Pat. No. 10,188,748

PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED MRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS

1. A cell-free mRNA pharmaceutical composition comprising at least one modified mRNA and a pharmaceutically compatible carrier, wherein the modified mRNA encodes at least one human tumour-specific antigenic polypeptide capable of stimulating an immune response in a patient against the human tumour-specific antigenic polypeptide wherein said modified mRNA encoding the human tumour-specific antigenic polypeptide has been stabilized by increasing its Guanosine/Cytosine (G/C) content by at least 7 percentage points relative to that of the wild type mRNA encoding the tumour-specific antigenic polypeptide.
US Pat. No. 10,188,749

COMPOSITIONS AND METHODS TO PROGRAM THERAPEUTIC CELLS USING TARGETED NUCLEIC ACID NANOCARRIERS

FRED HUTCHINSON CANCER RE...

1. A method of selectively modifying a selected cell population of hematopoietic origin comprising:(a) forming selected cell-targeted synthetic nanocarriers by
(i) adding polyglutamic acid (PGA) conjugated to selected cell targeting ligands that bind the selected cell population of hematopoietic origin to a solution comprising nucleic acid encapsulated within a positively-charged carrier comprising poly(?-amino ester); and
(ii) incubating the solution wherein selected cell-targeted synthetic nanocarriers form within 5 minutes of the adding and comprise
(A) nucleic acid encapsulated within the positively-charged carrier comprising poly(?-amino ester);
(B) a neutrally or negatively-charged coating comprising about a 15 kDa PGA on the outer surface of the positively-charged carrier; and
(C) the selected cell targeting ligands extending from the outer surface of the neutrally or negatively-charged coating and conjugated to PGA within the neutrally or negatively-charged coating; and
(b) administering the formed selected cell-targeted synthetic nanocarriers to a heterogenous mixture of ex vivo cells comprising the selected cell population of hematopoietic origin within a serum-free media thereby selectively modifying the selected cell population of hematopoietic origin.
US Pat. No. 10,190,031

THERMALLY CONDUCTIVE INTERFACE COMPOSITION AND USE THEREOF

Jiali Wu, Yorktown Heigh...

1. A thermally conductive interface composition, comprising:(A) A linear alkenyl organopolysiloxane containing a silicon-bonded alkenyl-terminated group or groups in an average amount of 0.0001 to 5 mol % based on the amount of all silicon-bonded organic groups contained per molecule;
(B) A branched alkenyl organopolysiloxane containing at least two silicon-bonded alkenyl groups in an average amount of about 0.01 to 1 mol % based on the amount of all silicon-bonded organic groups contained per molecule, with component (A) to (B) ratio of 20:1 to 1:20;
(C) Thermally conductive fillers in a ternary particle size mixture with large particle in the average size range of 50-500 um, small particle in the average size range of 0.5-200 um, and nanoparticle in the average size range of 10-2000 nm;
(D) An organohydrogenpolysiloxane containing at least two Si—H terminated groups presented at terminal or intermediate positions of the molecule, with 0.5-0.8 moles of SiH groups per mole of alkenyl groups in component (A) and (B);
(E) An addition reaction catalyst;
(F) A hydroxy group-containing siloxane in an amount corresponding to 0.0001-5% of the weight of component (A) and (B) combined;
(G) A mixture of at least two alkoxy group-containing siloxanes adhering to formula (5) differing in the value of “n” added in an amount corresponding to 0.001-5% of the weight of component (C)
(R8O)pSiR93-p[OSiR82]n(OR8)qR93-q  (5)
wherein R8 and R9 represent a substituted or unsubstituted monovalent hydrocarbon group, p is an integer of 1, 2, 03, q is an integer of 1, 2, or 3, and n is an integer of 1 to 150.
US Pat. No. 10,191,055

DETECTION OF ACUTE MYELOID LEUKAEMIA (AML) LEUKAEMIC STEM CELLS (LSC)

OXFORD UNIVERSITY INNOVAT...

2. The method according to claim 1 further comprising contacting the isolated sample with one or more selected from the group consisting of:an antibody that specifically binds to CD2;
an antibody that specifically binds to CD3;
an antibody that specifically binds to CD4;
an antibody that specifically binds to CD8a;
an antibody that specifically binds to CD10;
an antibody that specifically binds to CD19;
an antibody that specifically binds to CD20; and
an antibody that specifically binds to CD235a.
US Pat. No. 10,188,750

SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF

University of South Flori...

1. A polyribonucleotide comprising:a RNA molecule of interest (ROI), wherein the ROI is an RNA capable of being translated into p27;
a microRNA (miRNA) target sequence, wherein the miRNA target sequence is a target for miR-126, and wherein the miRNA target sequence is operatively linked to the ROI; and
a RNA molecule capable of being translated into a viral RNA replicase, wherein the RNA molecule capable of being translated into a viral RNA replicase is operatively linked to the ROI, the miRNA target sequence, or both the ROI and miRNA target sequence.
US Pat. No. 10,191,056

DIAGNOSTIC EVALUATION OF ANTIBODY RESPONSES TO COMMONLY RECOGNIZED PROSTATE CANCER-ASSOCIATED ANTIGENS

Wisconsin Alumni Research...

1. An antigen panel for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising antigens encoded by SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:91, the encoded antigens being immobilized on one of a membrane, a plate, and a filter, and having a positive likelihood ratio of at least 4.
US Pat. No. 10,188,751

PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS

The United States of Amer...

1. A method comprising administering to cancer cells in a subject, a papilloma pseudovirus that comprises a fluorescent dye or a papilloma virus-like particle (VLP) that comprises a fluorescent dye, and exposing the fluorescent dye in the cancer cells in the subject to an excitation wavelength of light.
US Pat. No. 10,189,008

ODOR AND COLOR STABLE WATER-ABSORBING COMPOSITION

Evonik Degussa GmbH, Ess...

1. A water-absorbing composition comprising at least: i) from 91.2 to 98.9 wt % of at least one water-absorbing polymer; ii) from 1 to 8 wt % of at least one oxidizing agent; and iii) from 0.1 to 0.75 wt % of at least one inhibitor to inhibit free-radical polymerizations; wherein the inhibitor is a hydroquinone or a hydroquinone derivative selected from the group consisting of hydroquinone, hydroquinone monomethyl ether (HQME), 1,4-dimethoxybenzene, 4,4?-oxydiphenol and a mixture of two or more thereof; and wherein the weight quantities are each based on the overall weight of the water-absorbing composition.
US Pat. No. 10,191,057

METHODS OF DIAGNOSING, CLASSIFYING AND TREATING ENDOMETRIAL CANCER AND PRECANCER

The Translational Genomic...

1. A method of treating endometrial cancer characterized by FGFR2 activation in a subject, the method comprising:obtaining from the subject a biological sample comprising endometrial cancer cells;
screening for a FGFR2 activation mutation in the endometrial cancer cells wherein the FGFR2 activation mutation results in an amino acid substitution selected from the group consisting of:
(a) an S to W mutation at position 252 of SEQ ID NOS:2 (NP_075259.2) or 3 (NP_000132.1);
(b) a P to R mutation at position 253 of SEC) ID NOS:2 or 3;
(c) a K to R mutation at position 310 of SEC) ID NOS:2 or 3;
(d) an A to T mutation at position 315 of SEQ ID NOS:2 or 3;
(e) an S to C mutation at position 373 of SEQ ID NO:2 or position 372 of SEQ ID NO:3;
(f) a Y to C mutation at position 376 of SEQ ID NO:2 or position 375 of SEQ ID NO:3;
(g) a C to R mutation at position 383 of SEQ ID NO:2 or position 382 of SEQ ID NO:3;
(h) an M to R mutation at position 392 of SEQ ID NO:2 or position 391 of SEQ ID NO:3;
(i) an I to V mutation at position 548 of SEQ ID NO:2 or position 547 of SEQ ID NO:3;
(j) an N to K mutation at position 550 of SEQ ID NO:2 or position 549 of SEQ ID NO:3;
(k) a K to E mutation at position 660 of SEQ ID NO:2 or position 659 of SEQ ID NO:3; and
(l) a K to N mutation at position 660 of SEQ ID NO:2 or position 659 of SEQ ID NO:3;
identifying the endometrial cancer cells as susceptible to an FGFR2 inhibitor upon finding the FGFR2 activation mutation in the endometrial cancer cells; and
administering to the subject with endometrial cancer characterized by FGFR2 activation an effective amount of an FGFR2 inhibitor, wherein the FGFR2 inhibitor is PD173074.
US Pat. No. 10,188,752

DUAL-MODALITY IMAGING PROBE FOR COMBINED LOCALIZATION AND APOPTOSIS DETECTION OF STEM CELLS

The Board of Trustees of ...

1. A dual-modality imaging probe for simultaneous, one-stop, cell apoptosis detection and stem cell tracking, comprising: ferumoxytol with a fluorescent signature peptide immobilized on the surface of the ferumoxytol, wherein the fluorescent signature peptide is a KKKKDEVD-AFC peptide (SEQ ID NO:1).
US Pat. No. 10,189,009

PARTICULATE WATER ABSORBING AGENT AND METHOD FOR MANUFACTURING SAME

NIPPON SHOKUBAI CO., LTD....

1. A method for producing a particulate water absorbing agent, the particulate water absorbing agent being arranged such that particles having passed through a 150-?m mesh as defined through a standard-sieve classification are contained in an amount of 3 mass % or less, the method comprising the steps of:(1) polymerizing a monomer aqueous solution including acrylic acid (salt) as a main component, the monomer aqueous solution having a monomer concentration of 30 mass % or more, the polymerization involving use of an internal crosslinking agent in an amount of 0.04 mol % or more and 0.07 mol % or less relative to the monomer and producing a hydrogel;
(2) drying the hydrogel, produced through the step (1), to produce a dried product having a swelling rate (CRC) of 35 g/g to 55 g/g;
(3) pulverizing the dried product into particles and optionally classifying the particles to produce a water absorbent resin powder including, at 80 mass % or more relative to the entire water absorbent resin powder, a particle having a size of 600 ?m to 150 ?m as defined through a standard-sieve classification;
(4) adding a surface-crosslinking agent, which includes a compound containing a hydroxyl group and/or a derivative group thereof, to the water absorbent resin powder, produced through the step (3), to decrease the swelling rate (CRC) by 3 g/g to 15 g/g to a swelling rate (CRC) of 32 g/g to 50 g/g to produce a surface-crosslinked water absorbent resin powder, and
(5) adding a liquid permeability improving agent to the water absorbent resin powder simultaneously with and/or after the step (4).
US Pat. No. 10,191,058

DIAGNOSIS OF CANCER BY DETECTING AUTO-ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR)

CELLTREND GMBH, Luckenwa...

1. A method for treating a vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) associated cancer, comprising(i) determining the level of antibodies against VEGFR in a sample from a subject suspected of having such cancer,
(ii) comparing the determined level in the sample to a control level of VEGFR antibodies derived from subjects without cancer;
(iii) identifying a subject having a decreased level of said antibodies in the subject's sample as compared to the level of said antibodies in the control, and
(iv) administering to the subject from step (iii) a drug selected from the group consisting of an angiogenesis inhibitor, an anti-VEGF antibody, and bevacizumab.
US Pat. No. 10,189,778

PROCESS FOR THE PREPARATION OF METHIONINE ALPHA-HYDROXY ANALOGUES FROM SUGARS AND DERIVATIVES THEREOF

1. A process for the preparation of a methionine ?-hydroxy analogue and derivatives thereof of the formula:R?—S—CH2—CH2—CHOH—COO—R  (I)wherein R is selected from the group consisting of H, C1-C8 alkyl, alkaline or alkaline-earth metals; and R? is selected from the group consisting of H and methyl; andwherein the process comprises a step of contacting one or more sugars or derivatives thereof selected from the group consisting of glucose, fructose, galactose, mannose, sucrose, xylose, erythrose, erythrulose, threose, glycolaldehyde, methyl vinyl glycolate,vinyl glycolic acid and 2-hydroxyl-?-butyrolactone with a metallo-silicate zeotype material, in the presence of a compound comprising sulphur and a solvent, wherein the metallo-silicate zeotype material has a framework structure selected from the group consisting of BEA, MFI, FAU, MOR, and FER, with a metal and/or metal oxide component.
US Pat. No. 10,191,059

IN VITRO METHOD FOR THE PROGNOSIS OF PROGRESSION OF A CANCER AND OF THE OUTCOME IN A PATIENT AND MEANS FOR PERFORMING SAID METHOD

Institut National de la S...

1. A method for treating a patient suffering from a solid cancer comprising the steps of:(i) evaluating the intra-tumor adaptive immune status of said patient before administration of an anti-cancer agent by quantifying, in a pre-administration tumor sample, at least two biological markers indicative of the status of the adaptive immune response of said patient against cancer, wherein two of said at least two biological markers are PDCD1LG1 combined with CD8A,
(ii) administering an anti-cancer agent to the patient,
(iii) evaluating the intra-tumor adaptive immune status of said patient after administration of said anti-cancer agent by quantifying in a post-administration tumor sample said at least two biological markers indicative of the status of the adaptive immune response of said patient against cancer,
(iv) comparing the levels of said at least two biological markers quantified in steps (i) with the levels of said at least two biological markers quantified in step (iii),
(v) administering to the patient:
a PDCD1LG1 inhibitor and/or a PDCD1 inhibitor to the patient when the level of PDCD1LG1 has increased between steps (i) and (iii); and/or
an immuno-stimulatory agent when the level of CD8A has not increased between step (i) and step (iii).
US Pat. No. 10,189,779

METHODS FOR PRODUCING THIOL COMPOUNDS AND SULFIDE COMPOUNDS USING DIPHENYLAMINE OR A PHENOL COMPOUND

Chevron Phillips Chemical...

1. A process for producing a thiol compound, the process comprising:i) contacting:
a) an olefin compound;
b) H2S;
c) diphenylamine and/or a phenol compound comprising BHT, carvacrol, 2,2?-ethylidene-bis(4,6-di-tert-butylphenol), pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate), or any combination thereof; and
d) a photoinitiator and/or a free radical initiator; and
ii) forming the thiol compound.
US Pat. No. 10,188,755

MAGNETIC MICROSTRUCTURES FOR MAGNETIC RESONANCE IMAGING

The United States of Amer...

1. A magnetic resonance contrast agent comprising one or a plurality of contrast structures, wherein each contrast structure consists of a single wall consisting of a magnetic material arranged as a substantially cylindrical magnetic structure with a length-to-diameter ratio between 0.8 and 1.6, wherein each contrast structure has a maximum dimension between about 10 nm and about 100 ?m, wherein each contrast structure defines an axially extending hollow region therethrough, and wherein the hollow region encompasses a spatially extended region contained within a near-field region of the contrast structure over which the structure on its own or in conjunction within an applied magnetic field results in a substantially homogeneous field, such that nuclear magnetic moments of a second material when arranged within said spatially extended region precess at a characteristic Larmor frequency, whereby the magnetic resonance contrast agent, combined with the second material, induces a characteristic magnetic resonance signal of the magnetic material.
US Pat. No. 10,189,013

MONOLITHIC CATALYST COMPRISING MOLECULAR SIEVE MEMBRANE AND METHOD FOR PREPARING THE MONOLITHIC CATALYST

WUHAN KAIDI ENGINEERING T...

1. A method for preparing a monolithic catalyst comprising:cobalt;
a matrix, the matrix comprising at least one metal selected from the group consisting of silver, gold, copper, platinum, titanium, molybdenum, iron, and tin;
an additive, the additive being lanthanum, zirconium, cerium, rhodium, platinum, rhenium, ruthenium, titanium, magnesium, calcium, strontium, or a mixture thereof; and
a molecular sieve membrane, the molecular sieve membrane being mesoporous silica SBA-16 which is disposed on a surface of the metal matrix and is a carrier of the cobalt and the additive;
wherein
a thickness of the carrier of the molecular sieve membrane is between 26 and 67 ?m, the method comprising:
1) washing a plurality of metal matrixes having a honeycomb-shape and uniform sizes using deionized water; and drying the metal matrixes in an oven at 100° C.;
2) dissolving molecular sieve powders of the mesoporous silica SBA-16 in absolute ethanol to yield a mixture; oscillating the mixture for 20 to 30 min using an ultrasonic oscillation method to form a uniformly distributed soak solution of the molecular sieve powders; soaking the metal matrixes pretreated in 1) in the soak solution for 1 to 10 s; taking the metal matrixes out, and when the soak solution on the metal matrixes stops flowing and dripping down, soaking the metal matrixes in the soak solution again; repeating the impregnation of the metal matrixes, and then drying the metal matrixes in air;
3) placing the metal matrixes obtained in 2) in a molecular sieve solution of mesoporous silica SBA-16 and crystallizing the mesoporous silica SBA-16 for 5 to 120 hrs at a temperature of between 70 and 150° C. in a reaction still; allowing the mesoporous silica SBA-16 to grow in-situ on a surface of the metal matrixes to yield metal matrixes comprising a molecular sieve membrane; taking out the metal matrixes comprising the molecular sieve membrane, washing the metal matrixes comprising the molecular sieve membrane using deionized water, and drying; and roasting the metal matrixes comprising the molecular sieve membrane for 4 to 8 hrs at a temperature of between 400 and 600° C.; and
4) soaking the metal matrixes comprising the molecular sieve membrane obtained in 3) in a solution of a cobalt salt and the additive for 1 to 20 min; drying the metal matrixes comprising the molecular sieve membrane and aging at room temperature for 3 to 36 hrs; roasting the metal matrixes comprising the molecular sieve membrane for 6 to 12 hrs at a programmed temperature of between 300 and 550° C., and then gradually cooling the metal matrixes comprising the molecular sieve membrane to room temperature.
US Pat. No. 10,188,757

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

The General Hospital Corp...

1. A method for treating Alzheimer's disease in a subject in need thereof comprising the steps of:a) administering to the subject by oral inhalation a dry powder formulation consisting essentially of 17.1 mg of micronized cromolyn sodium, 12.8 mg lactose monohydrate, and 0.6 mg micronized magnesium stearate; and
b) administering orally to the subject 1 mg, 2 mg, 5 mg, 10 mg, or 25 mg of a non-steroidal anti-inflammatory drug,
wherein Alzheimer's Disease is treated in the subject.
US Pat. No. 10,190,039

SYNTHETIC ACID COMPOSITIONS ALTERNATIVES TO CONVENTIONAL ACIDS IN THE OIL AND GAS INDUSTRY

FLUID ENERGY GROUP LTD., ...

1. A synthetic acid composition for use in oil industry activities, said composition comprising:urea and hydrogen chloride in a molar ratio of not less than 0.1:1; and
a metal iodide or iodate.
US Pat. No. 10,189,271

NON-FOAMING AQUEOUS PARTICLE-FREE INKJET INK COMPOSITIONS

EASTMAN KODAK COMPANY, R...

1. An aqueous colorless particle-free inkjet ink composition that has a viscosity of less than 5 centipoises (0.005 N-sec) at 25° C., and comprises:an anionic polyether polyurethane having an acid number of at least 50 and an anionic acrylic polymer or anionic styrene-acrylic polymer having an acid number of at least 50; wherein the weight ratio of the anionic polyether polyurethane to the anionic acrylic polymer or anionic styrene-acrylic polymer is from 1:9 to and including 9:1, and the total amount of the anionic polyether polyurethane and the anionic acrylic polymer or anionic styrene-acrylic polymer is less than or equal to 20 weight % based on the total aqueous colorless particle-free inkjet ink composition weight, and
a defoamer that has a hydrophilic-lipophilic balance value of at least 3 and up to and including 5, which defoamer is present in an amount of at least 0.15 weight % and up to and including 1 weight %, based on the total aqueous colorless particle-free inkjet ink composition weight.
US Pat. No. 10,191,064

THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY

Quest Diagnostics Investm...

1. A method for determining the amount of thyroglobulin in a test sample, comprising:(a) adding a thyroglobulin peptide standard in said test sample containing thyroglobulin peptides, wherein one or more valine of the thyroglobulin peptide standard is isotopically labeled with 13C, 15N;
(b) enriching said thyroglobulin peptides and thyroglobulin peptide standard from step (a);
(c) ionizing said thyroglobulin peptides and thyroglobulin peptide standard from step (b) to produce one or more thyroglobulin peptide ions and thyroglobulin peptide standard ions detectable by mass spectrometry; and
(d) detecting the amount of the ion(s) from step (c) by mass spectrometry; wherein the amount of the ion(s) detected in step (c) is related to the amount of thyroglobulin in said test sample and the amount of thyroglobulin peptide standard.
US Pat. No. 10,193,117

SEPARATOR FOR NONAQUEOUS SECONDARY BATTERY, AND NONAQUEOUS SECONDARY BATTERY

TEIJIN LIMITED, Osaka (J...

1. A separator for a nonaqueous secondary battery, comprising a porous substrate and an adhesive porous layer that is formed on at least one side of the porous substrate and contains a polyvinylidene-fluoride-based resin,the separator for a nonaqueous secondary battery being characterized in that the adhesive porous layer has a crystal size of 1 nm or more and 13 nm or less.
US Pat. No. 10,188,760

MODULATION OF IMMUNITY AND CEACAM1 ACTIVITY

1. A method for diagnosing a cancer in a human patient, said method comprising the step of contacting a biological sample derived from said patient with a CEACAM1 binding agent conjugated to a detectable moiety, wherein the CEACAM1 binding agent comprises a multimer agent consisting of at least two peptides selected from the group consisting of GYSWYK (SEQ ID NO:33), NRQII (SEQ ID NO:34), and QNDTG (SEQ ID NO: 35).
US Pat. No. 10,191,067

METHOD FOR IDENTIFYING AN AGENT FOR TREATING ABNORMAL KIDNEY FUNCTION

Proteomics International ...

1. A method of identifying an agent for treating or reducing the risk of developing abnormal kidney function, which is defined as an albumin creatinine ratio (ACR) of 3.5 or more, the method comprising:(i) contacting cells expressing at least one biomarker, wherein said at least one biomarker is CD5 antigen like, with a putative agent; and
(ii) comparing expression and/or levels of the at least one biomarker in the cells prior to contact with the putative agent to expression and/or levels of the at least one biomarker in the cells after contact with the putative agent;
wherein a change in the level or expression identifies the agent as an agent for treating or reducing the risk of developing abnormal kidney function.
US Pat. No. 10,191,068

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

ARIZONA BOARD OF REGENTS ...

1. An antibody fragment comprising an amino acid sequence encoded by a nucleic acid, wherein the nucleic acid has at least 96% identity to SEQ ID NO:1.
US Pat. No. 10,190,045

NANO-COMPOSITE STRUCTURE AND PROCESSES MAKING OF

1. A nano-composite structure comprising a nano-composite material having an amorphous matrix with embedded nano-crystallites, wherein the amorphous matrix and the nano-crystallites are made of the same chemical elements, wherein the nano-composite structure exhibits no distinguishable crystalline grain boundaries between the amorphous matrix and the nano-crystallites, wherein the nano-composite structure comprises multiple layers of nano-composite material, the multiple layers of nano-composite material disposed one directly on top of another in direct contact, and wherein each of the nano-composite layers consists of the nano-composite material.
US Pat. No. 10,191,069

ACCURATE ASSAY MEASUREMENT OF HYDROPHOBIC HAPTENIC ANALYTES

Siemens Healthcare Diagno...

1. A method of determining an actual concentration of a hydrophobic haptenic analyte in an unknown sample suspected of containing the hydrophobic haptenic analyte, wherein the unknown sample is suspected of containing an interfering substance, the method comprising:(a) conducting a first assay method on an unknown sample to obtain a measured concentration of the hydrophobic haptenic analyte in the unknown sample and conducting a second assay method on the unknown sample to obtain a concentration of the interfering substance in the unknown sample, wherein the hydrophobic haptenic analyte is selected from the group consisting of fat-soluble vitamins, steroid hormones, therapeutic drugs, and drugs of abuse, and wherein the interfering substance is lipoproteins; and
(b) applying a predetermined correction formula that utilizes the measured concentration of the hydrophobic haptenic analyte and the measured concentration of the interfering substance obtained in step (a) to determine an actual concentration of the hydrophobic haptenic analyte in the unknown sample, wherein the correction formula is predetermined by a method that comprises:
(i) measuring a concentration of the hydrophobic haptenic analyte for at least two different samples using the first assay method and measuring the concentration of the hydrophobic haptenic analyte for the at least two different samples using a reference method wherein the samples also comprise the interfering substance,
(ii) determining a bias between the first assay method and the reference method wherein the bias is the difference between the concentration of the hydrophobic haptenic analyte determined by the reference method and the first assay method for each different sample;
(iii) measuring a concentration of the interfering substance for the at least two different samples; and
(iv) determining the correction formula by conducting a regression analysis using the bias and the concentration of the interfering substance for each of the at least two different samples,wherein the regression analysis comprises forming a regression line and using the slope and intercept of the regression line to form the following correction formula:[An]=[mAn]+(a×[mIS]+b)wherein:[An] is the actual concentration of the hydrophobic haptenic analyte in the unknown sample,
[mAn] is the measured concentration of the hydrophobic haptenic analyte in the unknown sample,
[mIS] is the measured concentration of the interfering substance in the unknown sample,
a is the slope of the regression line, and
b is the intercept of the regression line; wherein the first assay method is an immunoassay method and wherein the reference method directly measures a character specific to the analyte and is different from the first assay method.
US Pat. No. 10,191,070

METHODS AND SYSTEMS FOR MEASURING SEROTONIN IN A SAMPLE

Laboratory Corporation of...

1. A method for determining amount of released serotonin in a sample, the method comprising:providing a sample comprising a biological sample, donor platelets, and heparin;
incubating the sample for a period of time to release serotonin from the donor platelets;
chromatographically separating serotonin from other components in the incubated sample using liquid chromatography; and
analyzing the chromatographically separated serotonin by mass spectrometry to determine the amount of released serotonin in the sample relative to a total amount of serotonin available in the donor platelets.
US Pat. No. 10,189,792

METHOD AND APPARATUS FOR SYNTHESIZING A WATER-SOLUBLE HEXAARYL BIIMIDAZOLE

1. A method for forming a water-soluble hexaaryl biimidazole, comprising the steps of:a) reacting benzil with a carboxy benzaldehyde and ammonium acetate to yield a carboxy triaryl imidazole; and
b) dimerizing said carboxy triaryl imidazole in an alkaline aqueous solution of potassium ferricyanide to yield a water-soluble salt of a bicarboxy hexaaryl biimidazole,
wherein said water-soluble salt of a bicarboxy hexaaryl biimidazole is the disodium salt of 2,2?-bicarboxy hexaaryl biimidazole.
US Pat. No. 10,188,772

DRUG DELIVERY MEDICAL DEVICE

Micell Technologies, Inc....

1. A medical device comprising:a balloon; and
a coating on at least a portion of the balloon,
wherein the coating comprises smooth and spherical particles having rapamycin particles encapsulated in a first polymer material prior to inclusion in the coating, the particles being from about 0.5 ?m to about 10 ?m in size and the first polymer being PLGA, and
wherein each particle is at least partially encapsulated in a second polymer material in the coating.
US Pat. No. 10,188,773

COMPOSITIONS AND DEVICES OF POLY-4-HYDROXYBUTYRATE

Tepha, Inc., Lexington, ...

1. A composition comprising a polyhydroxyalkanoate (PHA) polymer obtained by a process comprising: suspending a PHA polymer biomass in ethanol for a period of time effective to extract lipids into the ethanol, separating the PHA polymer biomass from the ethanol by solid-liquid separation, collecting the ethanol-washed biomass, and extracting the PHA polymer into a solvent.
US Pat. No. 10,193,132

SYNTHESIS OF SUBMICROMETER TO MICROMETER-SIZED CATHODE MATERIALS

Washington University, S...

1. A method of producing submicrometer- to micrometer-sized, spherical-shaped cathode materials for lithium ion batteries, the method comprising:dissolving a lithium salt and a metal salt in water, alcohol, oil or a mixture of any two or more thereof, forming a lithium metal precursor solution,
spraying the precursor solution to form fine aerosolized droplets,
flowing the aerosolized droplets in a carrier medium into a pyrolysis hydrogen flame producing submicrometer- to micrometer-sized spherical lithium-metal-oxide particles in a range of from about 0.1 ?m to about 100 ?m, wherein no external heat source is required, and wherein the droplets are flowing in an environment having a temperature of less than 1200° C., wherein the submicrometer- to micrometer-sized spherical-shaped lithium-metal-oxide particles produced have a formula of Li?M??O? wherein ? is 0???1; ? is 0???2; and ? is 0???4; and wherein M? is selected from the group consisting of Ni, Co, Mn, Al, Mg, Fe, Cu, Zn, V, Mo, Nb, Cr, Si, Ti, Zr, and a mixture of any two or more thereof.
US Pat. No. 10,188,774

METHOD FOR PRODUCING ANTITHROMBOTIC COATING MATERIAL

TERUMO KABUSHIKI KAISHA, ...

1. A method for producing an antithrombotic coating material, the method comprising:preparing a methanol solution containing a monomer consisting of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof;
adding a radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less to the methanol solution to prepare a polymerization reaction liquid, wherein the radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less is 2,2?-azobis(4-methoxy-2,4-dimethylvaleronitrile); and
polymerizing the monomer to form a polymer, wherein the monomer used to form the polymer consists of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof.
US Pat. No. 10,193,134

DOPED SODIUM MANGANESE OXIDE CATHODE MATERIAL FOR SODIUM ION BATTERIES

UMICORE, Brussels (BE) U...

1. A sodium transition metal cathode material for a rechargeable sodium battery, having a P2 layered bronze crystal structure and having a composition NaxMO2, M comprising at least 55 mol % manganese, wherein the manganese valence state is at least 3.75, wherein 2/3
US Pat. No. 10,193,138

GLASS-FIBER CONTAINING COMPOSITE MATERIALS FOR ALKALI METAL-BASED BATTERIES AND METHODS OF MAKING

Johns Manville, Denver, ...

1. A method of making a glass-fiber composite, the method comprising the steps of:forming a wet laid non-woven glass fiber substrate, wherein the glass fiber substrate comprises a sodium-based compound selected from the group consisting of NaMnO2; NaNiO2; Na(Ni0.5Mn0.5)O2, NaFePO4, Na2Fe2(SO4)3, and Na2Mn11[Mn11(CN)6]; and contacting alkali-metal containing particles on the substrate.
US Pat. No. 10,193,141

POSITIVE ELECTRODE MIXTURE AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY

TODA KOGYO CORPORATION, ...

1. A positive electrode mixture comprising carbon black having a bulk density of not more than 0.1 g/cm3, a crystallite size of 10 to 40 ?, an iodine adsorption of 1 to 150 mg/g, a volatile content of not more than 0.1% and a metal impurity content of not more than 20 ppm, and a positive electrode (cathode) active substance having an operating voltage or an initial crystal phase transition voltage of not less than 4.5 V on the basis of lithium.
US Pat. No. 10,188,783

METHOD FOR EXTRACORPOREAL REMOVAL OF PATHOGENIC MICROBE, AN INFLAMMATORY CELL OR AN INFLAMMATORY PROTEIN FROM BLOOD

ExThera Medical Corporati...

1. A method for extracorporeal removal of a virus from a subject, said method comprising:a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said virus in said subject's whole blood sample to the heparin;
b) separating the whole blood from the solid substrate;
c) recovering said whole blood containing a reduced amount of said virus; and
d) reintroducing into said subject said whole blood containing a reduced amount of said virus.
US Pat. No. 10,189,808

SOLID FORMS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES

Celgene Corporation, Sum...

1. A solid form of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a tautomer thereof, which is Form C having an X-ray powder diffraction pattern comprising peaks at about 16.7, 16.9, 17.7 or 24.7 degrees 2?.
US Pat. No. 10,193,143

NEGATIVE ELECTRODE ACTIVE MATERIAL FOR ELECTRICITY STORAGE DEVICES AND METHOD FOR PRODUCING SAME

NIPPON ELECTRIC GLASS CO....

1. A negative electrode active material for an electricity storage device, comprising a composition containing TiO2, Na2O, and a network-forming oxide, and comprising a precipitated crystal of a monoclinic crystal containing Na, Ti, and O.
US Pat. No. 10,193,144

HIGH CAPACITY LITHIUM ION BATTERIES HAVING OXIDES, PEROXIDES, OR SUPEROXIDES AS CATHODE ACTIVE MATERIAL

UCHICAGO ARGONNE, LLC, C...

1. A cathode comprising an electroactive material comprising LO2 or L2O2, wherein each L is independently selected from Li, Na, K, Be, Mg, Ca, and Al; the electroactive material is metal-coated, metal oxide-coated, or doped; the electroactive material has less than or equal to 10 wt. % of transition metal catalyst; and the electroactive material is non-cycled active material, wherein the electroactive material is doped with Li, Na, K, Be, Mg, Ca, Al, Cu, Mn, Nd, Ag, Ti, Ni, Cd, Ir, Ta, Y, Zr, Nb, Rh, or Cr.
US Pat. No. 10,189,811

METHOD FOR PREPARING THE ANHYDROUS CRYSTALLINE FORM OF ISONIAZID-DERIVED HYDRAZONE, THUS PRODUCED CRISTALLINE POLYMORPH OF THE ANHYDROUS FORM, USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSONISM AND OTHER NEURODEGENERATIVE DISORDERS, AND PH


US Pat. No. 10,190,071

STABILIZED BLENDS CONTAINING FRICTION MODIFIERS

The Lubrizol Corporation,...

1. A composition comprising:(a) a medium comprising a solvent, a functional fluid, an additive concentrate or combinations thereof; and
(b) a friction modifier component comprising a condensation product of tartaric and/or citric acid and a linear or branched fatty alcohol of 10 to 18 carbon atoms wherein said condensation product is not fully soluble in the medium; and
(c) a stabilizing component comprising a dispersant that is soluble in (a) and that interacts with (b) such that the solubility of (b) in (a) is improved, wherein said stabilizing component is present at about 4% to about 8% by weight of said composition;
wherein component (b) is present in component (a) in the form of dispersed particles wherein no more than 10 percent by weight of the particles have a diameter of more than 0.5 microns;
wherein component (b) is present in the overall composition at a level of 2 to 4 percent by weight;
wherein component (c), the stabilizing component, comprises: (i) a nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine; (ii) a borated nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine which is borated; (iii) an alkyl imidazoline derived from a polyalkylene amine and a fatty mono-carboxylic acid; or combinations thereof;
wherein a N:CO ratio of (i) or (ii) ranges from greater than 1.3:1 to about 2:1; and
wherein a TBN, as defined by ASTM D4739, of (iii) is greater than 9.
US Pat. No. 10,190,072

METHOD FOR IMPROVING ENGINE FUEL EFFICIENCY

EXXONMOBIL RESEARCH AND E...

1. A method for improving fuel efficiency and reducing frictional properties, while maintaining or improving deposit control, in an engine lubricated with a lubricating oil by using as the lubricating engine oil a formulated oil, said formulated oil having a composition comprising:from 75 to 95 wt % of lubricating oil base stock selected from the group consisting of a Group I base stock, a Group II base stock, a Group III base stock, a Group IV base stock, a Group V base stock and combinations thereof;
a friction modifier mixture comprising a polymeric ethoxylated fatty acid ester having a molecular weight of greater than or equal to 2000 at from 0.1 to 1.0 wt. % of the weight of the lubricating engine oil and an organic molybdenum containing friction modifier contributing from 80 ppm to 500 ppm of elemental molybdenum based on the weight of the lubricating engine oil, and
an overbased calcium salicylate detergent contributing from 200 ppm to 2000 ppm of elemental calcium based on the weight of the lubricating engine oil;
wherein the remainder of the lubricating engine oil includes one or more other lubricating oil additives;
wherein fuel efficiency and friction reduction properties are improved (mini-traction machine (MTM) in Stribeck mode friction coefficient at 140° C. less than or equal to 0.20) and deposit control is maintained or improved (TEOST 33C total deposits less than or equal to 30 mg) as compared to friction reduction properties and deposit control achieved using the same lubricating engine oil not containing the friction modifier mixture and the overbased calcium salicylate detergent.
US Pat. No. 10,190,074

COMPOSITION COMPRISING CHOLESTEROL

GOLDEN OMEGA S.A., Las C...

1. A process for producing a composition comprising at least 20% by weight of cholesterol, based on 100% total weight of the composition, the process comprising the steps of:(a) distilling a fish oil having at most 2% by weight of free fatty acids, based on 100% total weight of the fish oil, in an admixture with an auxiliary fluid in a vacuum distillation column to obtain a first distillate and a first residue; and
(b) distilling the first distillate in a vacuum distillation column to obtain a second distillate and a second residue, wherein (i) the second residue comprises the composition comprising at least 20% by weight cholesterol, based on the total weight of the composition, and (ii) the composition has a lower content of anthropogenic contaminants than the fish oil.
US Pat. No. 10,188,793

INSULIN ON BOARD CALCULATION, SCHEDULE AND DELIVERY

Bigfoot Biomedical, Inc.,...

1. An insulin delivery system comprising:an insulin delivery device configured to deliver insulin to a user of the system; and
a computer-based control unit associated with the insulin delivery device, the computer-based control unit having a computer-based processor, wherein the computer-based processor is configured to:
calculate a relative insulin on board value for a specific time by calculating a first value that represents a reference insulin on board value at the specific time, calculating a second value that represents an automated insulin on board value at the specific time, and subtracting one of the first and second values from the other;
determine a future insulin delivery schedule over a period of time based in part on the calculated relative insulin on board value; and
configure the insulin delivery device to deliver insulin according to the determined future insulin delivery schedule, and
wherein the automated insulin on board value represents at least one insulin delivery automatically specified by the computer-based control unit.
US Pat. No. 10,192,641

METHOD OF GENERATING A DYNAMIC PATHWAY MAP

The Regents of the Univer...

1. A processor-based method of generating a dynamic pathway map (DPM), comprising:accessing a model database that stores a probabilistic pathway model that comprises a plurality of pathway elements;
assigning an influence level for at least one pathway of a first number of the plurality of pathway elements on the basis of known attributes;
cross correlating the first number of the plurality of pathway elements;
assigning an influence level for at least one pathway on the basis of assumed attributes;
measuring a patient sample to identify measured attributes of the patient sample, based on a genome-scale assay;
modifying the probabilistic pathway model by using a plurality of the measured attributes for a plurality of elements of the patient sample, via an analysis engine, the modifying comprising:
obtaining a factor graph representing states of entities in a cell and interactions between the entities, wherein the factor graph encodes a state of the cell using a random variable for each entity and wherein the factor graph has reference pathway activity information for a particular pathway, the reference pathway indicating deviations from the probabilistic pathway model; and
formulating a treatment option for the patient based on the reference pathway activity of the factor graph, wherein at least one of the above method operations is performed through a processor.
US Pat. No. 10,191,365

REFLECTIVE MASK BLANK, METHOD OF MANUFACTURING REFLECTIVE MASK BLANK, REFLECTIVE MASK AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Shinju...

1. A reflective mask blank, comprising:a mask blank multilayer film that comprises a multilayer reflective film obtained by alternately laminating a high refractive index layer and a low refractive index layer, and
an absorber film on or above a main surface of a mask blank substrate;
wherein, the root mean square roughness (Rms), obtained by measuring a 3 ?m ×3 ?m region on a surface of the reflective mask blank on which the mask blank multilayer film is formed with an atomic force microscope, is not more than 0.5 nm and an integrated value of a power spectrum density at a spatial frequency of 1 ?m?1 to 10 ?m?1 is not more than 800×10?3 nm3.
US Pat. No. 10,190,086

METHODS OF PITCHING YEAST FOR FERMENTATION, AND RELATED METHODS OF FERMENTATION AND SYSTEMS

POET Research, Inc., Sio...

1. A method of pitching yeast for fermentation, the method comprising:providing a first aqueous composition in a first fermentation reactor, wherein the first aqueous composition comprises:
yeast;
a slurry comprising water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose;
fermenting the first aqueous composition in the first fermentation reactor to form a first beer composition comprising alcohol;
providing a fraction of the first beer composition to a second fermentation reactor, wherein the first beer composition in the first fermentation reactor comprises an alcohol at a concentration of at least 15 percent by volume when the fraction of the first beer composition is removed from the first fermentation reactor, and wherein the fraction of the first beer composition comprises a fraction of the yeast and the alcohol;
combining a slurry with the fraction of the first beer composition in the second fermentation reactor to form a second aqueous composition in the second fermentation reactor, wherein the slurry comprises water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose; and
distilling the first beer composition from the first fermentation reactor to recover alcohol.
US Pat. No. 10,191,366

ETCH VARIATION TOLERANT OPTIMIZATION

ASML Netherlands B.V., V...

1. A method to improve a lithographic process for imaging a portion of a design layout onto a substrate using a lithographic projection apparatus and for transferring the imaged portion of the design layout to the substrate by an etching process, the method comprising:determining a value of an evaluation point of the lithographic process for each of a plurality of variations of the etching process;
computing, by a hardware computer system, a multi-variable cost function of a plurality of design variables that are characteristics of the lithographic process, wherein the multi-variable cost function is a function of a deviation from the determined values of the evaluation point; and
reconfiguring one or more of the characteristics of the lithographic process by adjusting one or more of the design variables and re-evaluating the cost function, until a termination condition for the cost function is satisfied.
US Pat. No. 10,190,091

METHODS OF CELL SEPARATION

CELLS 4 LIFE GROUP LLP, ...

1. A method for separating cells, said method comprising:(a) contacting a blood cell-containing sample containing erythrocyte blood cells with:
(i) a macromolecular erythrocyte sedimentation enhancer, and
(ii) dimethyl sulphoxide (DMSO), dimethylglycine (DMG) and/or valine;
(b) allowing said sample to partition into a sedimented phase and a supernatant phase; and
(c) recovering non-erythrocyte blood cells from said supernatant phase;
wherein in step (a), when the sample is contacted with components (i) and (ii), the resulting mixture comprises component (i) at a concentration of 0.01 to 10% w/v, and component (ii) at a concentration of 0.01 to 10% w/v.
US Pat. No. 10,191,371

UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER

ROHM AND HAAS ELECTRONIC ...

1. An underlayer comprising:an acid sensitive copolymer comprising:
an acid decomposable group;
an attachment group; and
a functional group; and
a photoacid generator,
where the functional group is operative to adjust neutrality of the acid-sensitive copolymer relative to a self-assembling block copolymer that is to be disposed on the underlayer, where the neutrality means that a surface energy of the underlayer is substantially the same as that of at least one block of the block copolymer;
wherein the attachment group is covalently bonded to a hydrophilic surface of a substrate by alkoxide linkages where the attachment group comprises a thiol, a primary or secondary amine substituted, a straight chain or branched C1-30 alkyl, a C3-30 cycloalkyl, a C6-30 aryl, a C7-30 alkaryl, a C7-30 aralkyl, a C1-30 heteroalkyl, a C3-30 heterocycloalkyl, a C6-30 heteroaryl, a C7-30 heteroalkaryl, a C7-30 heteroaralkyl, or a combination comprising at least one of these groups; and wherein the acid decomposable groups are ester groups, acetal groups, ketal groups, or pyrocarbonate groups.
US Pat. No. 10,190,092

PROCUREMENT OF PLACENTAL STEM CELLS

1. A method for collecting stem cells from a placenta obtained after childbirth, the method comprising:draining cord blood from the placenta obtained after childbirth;
collecting the drained cord blood in a first collection;
infusing the drained placenta with a first solution, the first solution consisting of a placental preservative base solution and prostaglandin, wherein the placental preservative base solution consists of NaCl, KCl, glucose, citric acid, adenine, histidine, glutamate, glutathione, and N-acetyl-L-cysteine;
infusing the placenta with a second solution before the first solution is collected, the second solution consisting of said placental preservative base solution, a stem cell releasing agent, an antibiotic, and an anticoagulant, wherein the stem cell releasing agent is 1, 1?-[1,4-phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutically acceptable salt thereof;
waiting for a predetermined amount of time as the first and second solutions perfuse the placenta, wherein said predetermined amount of time is 5 minutes or fewer; and
collecting, in a second collection, said first and second solutions from the placenta, wherein the collected first and second solutions comprise stem cells from the placenta.
US Pat. No. 10,190,093

ARTIFICIAL OOCYTE ACTIVATION

The Curators of the Unive...

1. A method of activating an unfertilized porcine oocyte comprising decreasing intracellular Zn2+ concentration of the oocyte by contacting the oocyte with a Zn2+ binding moiety comprising approximately 200 mM TPEN (N,N,N?,N?-tetrakis(2-pyridylmethyl)ethane-1,2-diamine), and increasing intracellular Ca2+ concentration of the oocyte prior to decreasing the intracellular Zn2+ concentration of the oocyte, wherein the intracellular Ca2+ concentration of the oocyte is not increased in an amount sufficient to induce oocyte activation, and wherein said contacting results in activating the oocyte.
US Pat. No. 10,191,373

METHOD FOR PRODUCING POLYMER

SHIN-ETSU CHEMICAL CO., L...

1. A method for producing a polymer comprising recurring units having an acid generator bound to the backbone, comprisingpolymerizing monomers corresponding to the recurring units in a solution of a non-polymerizable compound containing at least one nitrogen atom to which at least one acid labile group is bound.
US Pat. No. 10,189,837

CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT

Medivation Technologies L...

4. A pharmaceutical composition comprising the crystalline tosylate salt of claim 1 and a pharmaceutically acceptable excipient.
US Pat. No. 10,190,094

METHODS AND COMPOSITIONS RELATED TO INDUCED SENSORY NEURONS

The Scripps Research Inst...

1. A method for generating induced sensory neurons (iSNs), comprising co-expressing Brn3A and Ngn1 genes via one or more expression vectors harboring Brn3A and Ngn1 genomic or cDNA sequences in a non-neuronal cell, thereby generating induced sensory neurons, wherein the non-neuronal cell is a fibroblast or a stem cell from a mammal.
US Pat. No. 10,193,171

FUEL CELL WITH INTEGRATED WATER MANAGEMENT LAYER AND FABRICATION METHOD THEREOF

1. Fabrication method of a fuel cell comprising the following successive steps:providing a substrate comprising:
at least one membrane-electrode assembly, formed by an electrolytic membrane arranged between a first electrode and a second electrode,
a first current collector arranged on the first electrode,
depositing a fluoropolymer solution on the first current collector,
making a solvent of the fluoropolymer solution evaporate so as to form a porous thin layer of fluoropolymer.
US Pat. No. 10,190,095

MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

Cornell Research Foundati...

1. An in vitro method of obtaining human oligodendrocyte progenitor cells, said method comprising:providing a mixed population containing human brain or spinal cord cell types;
removing neurons and neuronal progenitor cells expressing polysialylated N-CAM (PSA-NCAM) from the mixed population to produce a treated mixed population; and
removing the oligodendrocyte progenitor cells expressing A2B5 from the treated mixed population to form an enriched population of A2B5+/PSA-NCAM? oligodendrocyte progenitor cells.
US Pat. No. 10,190,096

METHODS FOR GENERATING STEM CELL-DERIVED ? CELLS AND USES THEREOF

President and Fellows of ...

1. A method for generating stem cell-derived ? (SC-?) cells, the method comprising contacting a cell population comprising endocrine progenitor cells under conditions suitable to direct differentiation of said endocrine progenitor cells into said SC-? cells with an effective amount of an agent that decreases the level and/or activity of c-Jun N-terminal kinase (JNK), thereby generating said SC-? cells, wherein the endocrine progenitor cells comprise PDX1+/NKX6.1+/NEUROD1+/insulin+/glucagon?/somatostatin? cells.
US Pat. No. 10,190,097

METHOD AND COMPOSITION FOR INDUCING HUMAN PLURIPOTENT STEM CELLS

The Regents of the Univer...

1. A method of pluripotency reprogramming, comprising:treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and
changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms;
wherein the FreP cell expresses NANOG and does not form teratoma, and
wherein the human cell is a fibroblastic cell.
US Pat. No. 10,190,098

AAV VECTORS PRODUCED BY INSECT CELLS COMPRISING REP52 AND REP78 CODING SEQUENCES WITH DIFFERENTIAL CODON BIASES

UniQure IP B.V., Amsterd...

1. A recombinant adeno-associated virus (rAAV) virion obtainable by culturing an insect cell under conditions such that rAAV virions are produced and recovering the rAAV virions, wherein the insect cell comprises a baculoviral vector comprising:(i) a first nucleotide sequence encoding a first amino acid sequence of an AAV Rep52 protein selected from the group consisting of:
(a) a sequence of at least 85% identity with SEQ ID NO: 10;
(b) a nucleotide sequence complementary to the full length sequence of (a); and
(c) a nucleotide sequence that differs from the sequence of (a) due to degeneracy of the genetic code; and
(ii) a second nucleotide sequence encoding a second amino acid sequence of an AAV Rep78 protein;
(iii) a third nucleotide sequence comprising two AAV inverted terminal repeat (ITR) sequences and a nucleotide sequence encoding a gene product of interest located between the two AAV ITR sequences; and,
(iv) a fourth nucleotide sequence comprising AAV capsid protein-coding sequences operably linked to expression control sequences for expression in an insect cell;
wherein the first and the second amino acid sequences share at least 90% sequence identity in a region from the second amino acid residue to the C-terminal residue of the AAV Rep52 protein, and
wherein a portion of the first nucleotide sequence and a portion of the second nucleotide sequence that encode the region from the second amino acid residue to the C-terminal residue of the AAV Rep52 protein each comprise one or more contiguous stretches of at least 300 nucleotides that are less than 90% identical.
US Pat. No. 10,192,661

R—T—B BASED SINTERED MAGNET

TDK CORPORATION, Tokyo (...

1. A R-T-B based sintered magnet, wherein:R contains Y and R1,
Y is yttrium,
R1 is at least one rare earth element except Y but contains Nd, and
T represents at least one transition metal element containing Fe or a combination of Fe and Co,
a ratio of R1 to Y (R1:Y) in a grain boundary phase is 73:27 to 55:45 in terms of a calculated molar ratio of the grain boundary phase.
US Pat. No. 10,190,099

IBV STRAINS AND USES THEREOF

BIOMUNE COMPANY, Lenexa,...

1. A method for protecting or vaccinating poultry against infectious bronchitis virus, comprising orally administering to said poultry an attenuated infectious bronchitis virus (IBV), wherein said attenuated IBV comprises a S1 gene having a nucleotide sequence with at least 98% identity to SEQ ID NO: 1, and wherein said attenuated IBV is formulated in gel drops.
US Pat. No. 10,190,102

LACCASE VARIANTS WITH IMPROVED PROPERTIES

METGEN OY, Kaarina (FI)

1. A polypeptide with laccase activity comprising an amino acid sequence that is at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NOS: 1 and 31-61, wherein the polypeptide comprises a non-polar amino acid residue selected from the group consisting of methionine, leucine, isoleucine, valine, proline, glycine, and phenylalanine at an amino acid position corresponding to position 113 in SEQ ID NO: 1.
US Pat. No. 10,188,052

MAIZE PLANTS WITH IMPROVED PATHOGEN RESISTANCE

Monsanto Technology LLC, ...

1. A method of obtaining a corn plant with improved tar spot complex (TARSC) resistance, said method comprising:a) providing a population of corn plants;
b) obtaining at least one DNA sample from at least one plant within said population;
c) detecting in the DNA sample the presence of a TARSC resistance allele comprising a “T” at nucleotide position 61 of SEQ ID NO: 6 in, or genetically linked to, a chromosomal segment between about 3.99 cM and about 17.7 cM on chromosome 10;
d) selecting one or more plants from said population based on the presence of said allele;
e) crossing at least one selected plant comprising said allele with a second corn plant that comprises one or zero TARSC resistance alleles to produce one or more progeny plants that produce seeds;
f) collecting the seeds produced by the one or more progeny plants; and
g) growing from said seeds at least one plant having said allele and having improved TARSC resistance.
US Pat. No. 10,190,103

POLYPEPTIDES HAVING GLUCURONYL ESTERASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

1. A method for degrading or hydrolyzing a cellulosic material, comprising: contacting the cellulosic material with an enzyme composition and an isolated polypeptide having glucuronyl esterase activity to thereby degrade or hydrolyze the cellulosic material, wherein the isolated polypeptide having glucuronyl esterase activity is selected from the group consisting of:(a) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2;
(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with the full-length complement of the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1, wherein the high stringency conditions are defined as prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, and washing three times each for 15 minutes using 2×SSC, 0.2% SDS at 65° C.;
(c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1; and
(d) a fragment of the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2, wherein the fragment has glucuronyl esterase activity.
US Pat. No. 10,188,054

HYBRID TOMATO VARIETY 72-191 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum plant designated 72-191 RZ, representative seed of which having been deposited under NCIMB Accession No. 42733.
US Pat. No. 10,189,080

METHOD FOR PRODUCING AN ENGINE COMPONENT, ENGINE COMPONENT, AND USE OF AN ALUMINIUM ALLOY

Federal-Mogul Nurnberg, ...

1. A method of producing an engine component by gravity die casting,wherein an aluminium alloy is cast consisting of the following alloy elements:
Silicon: 9% by weight to ?10.5% by weight,
Nickel: >2.0% by weight to <3.5% by weight,
Copper: >3.7% by weight to 5.2% by weight,
Cobalt: to <1% by weight,
Magnesium: 0.5% by weight to 1.5% by weight,
Iron: 0.1% by weight to 0.7% by weight,
Manganese: 0.1% by weight to 0.4% by weight,
Zirconium: >0.1% by weight to <0.2% by weight,
Vanadium: >0.1% by weight to <0.2% by weight,
Titanium: 0.05% by weight to <0.2% by weight,
Phosphorus: 0.004% by weight to 0.008% by weight,
with aluminium and unavoidable impurities constituting the rest.
US Pat. No. 10,190,105

HBV POLYMERASE MUTANTS

Transgene S.A., Illkirch...

1. A mutant polypeptide which comprises a mutated HBV polymerase domain with an internal deletion that functionally disrupts the polymerase activity, wherein said internal deletion is of at least 4 amino acid residues and at most 30 amino acid residues, wherein said mutated polymerase domain comprises the amino acid sequence shown in SEQ ID NO:1 but lacks at least the Tyr residue in position 203, the Met residue in position 204, the Asp residue in position 205 and the Asp residue in position 206, the Val residue in position 207, the Val residue in position 208, and the Leu residue in position 209.
US Pat. No. 10,188,055

WATERMELON LINE ACE PLUS

SAKATA SEED AMERICA, INC....

1. A seed of watermelon line Ace Plus, wherein a representative sample of seed of said line was deposited under ATCC Accession No. PTA-125206.
US Pat. No. 10,190,106

CAS9-DNA TARGETING UNIT CHIMERAS

Univesity of Massachusett...

1. A fusion protein comprising an attenuated Streptococcus pyogenes Cas9 (SpCas9) nuclease, said nuclease comprising a protospacer adjacent motif recognition domain having a lysine-substituted or serine substituted arginine residue and a DNA binding domain (DBD) protein.
US Pat. No. 10,193,183

NONAQUEOUS ELECTROLYTE SECONDARY BATTERIES

SANYO Electric Co., Ltd.,...

1. A nonaqueous electrolyte secondary battery comprising a positive electrode including a lithium transition metal oxide, a negative electrode including a negative electrode active material capable of storing and releasing lithium ions, and a nonaqueous electrolyte,the negative electrode active material including a carbon material as a main component,
the negative electrode including a lithium tungsten composite oxide and/or a lithium molybdenum composite oxide.
US Pat. No. 10,188,056

HYBRID TOMATO VARIETY 72-762 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum tomato plant designated 72-762 RZ, representative seed of which having been deposited under NCIMB Accession No. 42810.
US Pat. No. 10,188,057

SOYBEAN CULTIVAR CL1462431

Syngenta Participations A...

1. A plant, a plant part, or a seed of soybean variety CL1462431, wherein a representative sample of seed of said soybean variety CL1462431 has been deposited under ATCC Accession Number PTA-123834.
US Pat. No. 10,190,108

METHOD FOR REDUCING VISCOSITY IN SACCHARIFICATION PROCESS

DANISCO US INC., Palo Al...

1. A biomass saccharification mixture comprising:a. a pretreated biomass material; and
b. a non-naturally occurring enzyme composition comprising a glycosyl hydrolase family 61 (“GH61”) polypeptide having GH61/endoglucanase activity, wherein the GH61 polypeptide
i) has at least 65% in sequence identity to residues 22-344 of SEQ ID NO:27; or
ii) is encoded by a polynucleotide sequence or a complement thereof that has at least 65% sequence identity to SEQ ID NO:30; or
iii) is encoded by a polynucleotide sequence that hybridizes under high stringency conditions to a sequence that is complementary to SEQ ID NO:30;
wherein the enzyme composition is a whole cellulase comprising at least one polypeptide having cellobiohydrolase activity, at least one polypeptide having endoglucanase activity that is different from the GH61 polypeptide, and at least one polypeptide having beta-glucosidase activity and wherein the whole cellulase is derived from a host cell containing a heterologous expression cassette comprising a nucleic acid encoding the GH61 polypeptide, wherein the GH61 polypeptide is present in the whole cellulase in an amount of at least 6 wt % and no more than 50 wt % based on the total weight of protein in the whole cellulase and wherein said biomass saccharification mixture has a lower viscosity than a biomass saccharification mixture without the GH61 polypeptide and/or is capable of increasing the level of saccharification in the mixture as compared to the level of saccharification in a mixture having no or a lower level of GH-61 polypeptide.
US Pat. No. 10,188,058

SWEET CORN HYBRID SVSK6143 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SHY-6S15-9078LP or corn line SHY-6RHBE322, a sample of seed of said lines having been deposited under ATCC Accession Number PTA-124211 and ATCC Accession Number PTA-124212, respectively.